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Human Chimeric Antigen Receptor Macrophages For Cancer Immunotherapy
Abstract
Despite recent landmark advances in chimeric antigen receptor (CAR) T cell immunotherapy for the
treatment of human cancer, metastatic solid tumors remain an intractable challenge. Myeloid cells are
actively recruited to the tumor microenvironment (TME), where tumor associated macrophages (TAMs)
are often the most abundant infiltrating immune cell. Currently, macrophage orientated
immunotherapeutic approaches under clinical development in oncology seek to reduce TAM infiltration or
enhance TAM phagocytosis. We hypothesized that genetically engineering human macrophages with
CARs against tumor-associated antigens could redirect their phagocytic activity and lead to therapeutic
efficacy with the potential for the induction of an anti-tumor T cell response.
In this thesis, we demonstrate that CD3-zeta based CARs are capable of inducing phagocytosis by human
macrophages. Notably, an active intracellular CAR signaling domain was required for activity. Targeted
phagocytosis and clearance of CD19+, mesothelin+, and HER2+ cells by CARs targeted against each
respective antigen was significantly superior to that by control untransduced (UTD) macrophages.
Importantly, CAR macrophages were capable of polyphagocytosis and serial phagocytosis of tumor cells.
We demonstrate that primary human monocyte derived macrophages, which are resistant to most viral
vectors, are efficiently transduced by the chimeric-fiber adenoviral vector Ad5f35. Ad5f35 transduced
primary human CAR macrophages demonstrated targeted phagocytosis, with phagocytic activity
dependent on both the CAR and antigen densities. CAR, but not UTD, macrophages led to potent dosedependent killing of tumor cells in vitro and led to tumor regression and improved overall survival in
murine xenograft models of human cancer.
Macrophage transduction with Ad5f35 leads to a broad gene expression change, an interferon signaling
signature, and induction of a classically activated M1 phenotype. CAR macrophages upregulated costimulatory ligand and antigen processing/presentation genes and led to enhanced T cell stimulation in
vitro and in vivo. Lastly, CAR, but not UTD, macrophages showed a broad resistance for M2 conversion in
response to immunosuppressive cytokines.
In conclusion, human CAR macrophages display targeted tumor phagocytosis, lead to improved overall
survival in xenograft models, and demonstrate enhanced T cell stimulation. Taken together, these data
show that CAR macrophages are a novel cell therapy platform for the treatment of human cancer.
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ABSTRACT
HUMAN CHIMERIC ANTIGEN RECEPTOR MACROPHAGES FOR CANCER
IMMUNOTHERAPY
Michael Klichinsky, PharmD
Saar Gill, MD PhD
Carl H. June, MD

Despite recent landmark advances in chimeric antigen receptor (CAR) T cell
immunotherapy for the treatment of human cancer, metastatic solid tumors remain an
intractable challenge. Myeloid cells are actively recruited to the tumor microenvironment
(TME), where tumor associated macrophages (TAMs) are often the most abundant
infiltrating immune cell. Currently, macrophage orientated immunotherapeutic
approaches under clinical development in oncology seek to reduce TAM infiltration or
enhance TAM phagocytosis. We hypothesized that genetically engineering human
macrophages with CARs against tumor-associated antigens could redirect their
phagocytic activity and lead to therapeutic efficacy with the potential for the induction of
an anti-tumor T cell response.
In this thesis, we demonstrate that CD3-zeta based CARs are capable of inducing
phagocytosis by human macrophages. Notably, an active intracellular CAR signaling
domain was required for activity. Targeted phagocytosis and clearance of CD19+,
mesothelin+, and HER2+ cells by CARs targeted against each respective antigen was
significantly superior to that by control untransduced (UTD) macrophages. Importantly,
v

CAR macrophages were capable of polyphagocytosis and serial phagocytosis of tumor
cells.
We demonstrate that primary human monocyte derived macrophages, which are resistant
to most viral vectors, are efficiently transduced by the chimeric-fiber adenoviral vector
Ad5f35. Ad5f35 transduced primary human CAR macrophages demonstrated targeted
phagocytosis, with phagocytic activity dependent on both the CAR and antigen densities.
CAR, but not UTD, macrophages led to potent dose-dependent killing of tumor cells in
vitro and led to tumor regression and improved overall survival in murine xenograft
models of human cancer.
Macrophage transduction with Ad5f35 leads to a broad gene expression change, an
interferon signaling signature, and induction of a classically activated M1 phenotype.
CAR macrophages upregulated co-stimulatory ligand and antigen processing/presentation
genes and led to enhanced T cell stimulation in vitro and in vivo. Lastly, CAR, but not
UTD, macrophages showed a broad resistance for M2 conversion in response to
immunosuppressive cytokines.
In conclusion, human CAR macrophages display targeted tumor phagocytosis, lead to
improved overall survival in xenograft models, and demonstrate enhanced T cell
stimulation. Taken together, these data show that CAR macrophages are a novel cell
therapy platform for the treatment of human cancer.
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CHAPTER 1. Introduction

Overview
Immunotherapy has been solidified as one of the pillars in modern cancer treatment. In
particular, chimeric antigen receptor (CAR) T cells have demonstrated unprecedented
efficacy in relapsed and refractory hematologic malignancy. Despite the success in
leukemia, lymphoma, and myeloma, the response to T cell based adoptive cellular
therapy in metastatic solid tumors has been minimal. Though the mechanism of
resistance is not clearly understood, the role of the tumor microenvironment, consisting
of the non-neoplastic cells within a tumor, is likely paramount to the inhibitory effect
tumors have on tumor reactive T cells. Studies have shown that macrophages are a key
component of the tumor microenvironment and aid in the development of all known
hallmarks of tumor development, invasion, and metastasis. Accordingly, macrophages
are often the most abundant leukocyte in the microenvironment of common human solid
tumors.
Given the active recruitment of myeloid cells to tumors, we hypothesized that genetically
engineering macrophages with chimeric antigen receptors may be an effective approach
to attacking cancer. In essence, the mechanism of the approach can be described with the
“Trojan Horse” analogy – in which the tumor recruits macrophages to feed its protumoral and immune-suppressive milieu, but the engineered macrophages are rewired to
attack the tumor in response to surface bound tumor associated antigens. Furthermore,
given that macrophages are sentinel cells of the immune system and professional antigen
1

presenting cells (APCs), they have the potential to initiate an adaptive immune response
against tumor neoantigens via the process of antigen processing and presentation.
In this thesis, we explore the concept of rewiring macrophage activity through genetic
manipulation. We test the hypothesis that phagocytosis can be programmed via chimeric
antigen receptor introduction into human macrophages. We evaluate the anti-tumor
potential of CAR macrophages targeted against relevant human tumor associated antigens
in relevant in vitro and in vivo models of human cancer. Importantly, this work utilizes
primary human monocyte derived macrophages, and thus has immediate potential for
translation into clinical studies.
Finally, we assess the role of phenotype on the activity of ex vivo differentiated CAR
macrophages and assess the potential for passive induction of the anti-tumor proinflammatory macrophage phenotype by using an immunostimulatory viral vector.
Furthermore, the potential for downstream subversion of CAR macrophage phenotype
toward a tumor-promoting M2 state in response to immunosuppressive cytokines is
assessed.
The data presented and discussed in this thesis introduce, for the first time, the concept of
targeting cancer with chimeric antigen receptor macrophages. By genetically
manipulating macrophages, we show that these innate immune cells can be bestowed
with adaptive specificity. Given the importance of immunotherapeutic approaches to the
treatment of human cancer, and the paramount medical need in the setting of metastatic

2

solid tumors, the therapeutic approach presented in this thesis introduces a novel cellular
immunotherapeutic platform with direct translational potential for human disease.

3

Cancer, the immune system, and the role of macrophages

Cancer

The discovery of the language that encodes life – DNA – unlocked our understanding of
the mechanism by which information is processed and transmitted both horizontally (cell
division) and vertically (reproduction). Insight into the replication and fidelity of the
genetic code provides insight into the mechanisms of Darwinian evolution and one of the
most complex diseases in modern man – cancer. The mechanisms for the development of
cancer are fundamentally rooted in Darwinian evolution. Random mutations provide for
genetic diversity. The human haploid genome is composed of 3.2x109 nucleotides, and
our DNA replication machinery has an error rate of approximately 1x10-8 – one error per
every hundred million bases replicated. DNA replication machinery has built-in error
detection and correction mechanisms, with a proof-reading and correction rate of
approximately 99%. Taken together, these estimates suggest that the error rate of human
DNA replication is approximately 1x10-10 – one error per every ten billion bases
replicated. On average there are 0.32 mutations per every genome replication event.
Though environmental factors such as carcinogen exposure or rare inherited mutations
enhance the risk of cancer formation by accelerating mutation rate, the occurrence of
cancer is a matter of stochasticity and probability. If there are 0.32 uncorrected mutations
per each genomic replication, and the average adult human body is estimated to be
composed of trillions of cells, there is a clear potential for the random occurrence of a
4

non-synonymous mutation in genes that allow for the uncontrolled proliferation and
avoidance of apoptosis that lead to cancer. The necessity for non-synonymous and nonbiochemically inert mutations in proto-oncogenes and tumor suppressor genes for the
induction of cancer further reduce the likelihood of transformation by several orders of
magnitude. While these rough estimates and considerations are fundamental to the
understanding of cancer, the real test is in the epidemiology of the disease.
As of 2015, 38.4% of men or women will develop and receive a cancer diagnosis in their
lifetimes. In 2018, there are an estimated 1.7x106 new cases of cancer in the United States
alone, with an approximately 6.1x105 cancer deaths. In 2018, the most common cancers
in the US are (from most to least frequent): breast cancer, lung cancer, prostate cancer,
colon and rectal cancer, melanoma, bladder cancer, non-Hodgkin lymphoma, kidney
cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer.
Logically, the incidence of cancer increases with age, and as the median lifespan of our
population increases, so does the incidence of cancer. Despite a continuing trend of
increased numbers of cancer diagnoses, the overall rate of cancer deaths in the United
States has decreased by 25% between 1990 and 2014 – highlighting the progress that has
been made in early detection, surgical technique, radiotherapy, and pharmacologic
treatment.
While the acquisition of multiple, random, synergistic mutations in proto-oncogenes and
tumor suppressor genes underlies all cancers, the term cancer encompasses a broad
family of diverse diseases with unique characteristics, pathologies, and responses to
5

treatment. Hanahan and Weinberg proposed a number of characteristics which underlie
the development of cancer, including: self-sufficiency in growth signals, insensitivity to
anti-growth signals, evasion of programmed cell-death, limitless replicative potential,
sustained angiogenesis, and tissue invasion/metastasis (Hanahan & Weinberg 2000).
While the initial transformation of a normal cell into a neoplastic cell is a cell-intrinsic
event, the impact of surrounding normal tissue on the development of the tumor is of
paramount importance to the growth, survival, immune evasion, invasion, and metastasis
of tumors. The term “tumor microenvironment” (TME) describes the infiltrating milieu
of non-neoplastic cells within a tumor, including stromal cells, fibroblasts, endothelial
cells, podocytes, and leukocytes. In this thesis, we describe the role of macrophages in
the tumor microenvironment, methods by which they exert protumor function, and
approaches to harness their effector function against cancer.

The tumor microenvironment and cancer immunity

As neoplastic cells grow, they require the orchestration of a complex series of events in
order to form tumors – a phenomenon which neoplastic cells cannot perform on their
own. Organs are composed of various tissues and cell types performing independent roles
which complement each other’s functions. In addition, cells within an organ are
constantly communicating via various feedback and regulatory mechanisms. Tumors,
like organs, consist of a variety of cell types in addition to neoplastic cells, with the
6

specific subtypes of normal cells present and their relative abundances varying amongst
tumor types and individual patients. The TME is composed of a heterogenous mixture of
the following non-neoplastic cells: monocytes, macrophages, myeloid precursors,
myeloid derived suppressor cells, granulocytes, granulocyte precursors, cytotoxic T cells,
regulatory T cells, NK cells, plasma cells, fibroblasts, stromal cells, mesenchymal stem
cells, endothelial cells, podocytes, and others.
Given that cancer is a disease founded on genetic mutation, non-synonymous mutations
in protein-coding genes have the potential to produce neoantigens. Early studies in the
laboratory of Robert Schreiber showed that cells of the immune system, specifically T
cells, have the potential to react against tumor cells carrying neoantigens via MHC-I
peptide complex recognition and cytolysis by CD8+ cytotoxic T lymphocytes. Schreiber
demonstrated that tumors readily engrafted in genetically engineered immunodeficient
mice, but often failed to grow in immunocompetent mice of the same genetic background
in the same period of time. In addition, when CD8+ T cells were genetically inhibited or
pharmacologic depleted in immunocompetent mice, tumor engraftment and growth
improved. These results suggest that while tumors consist of host self-cells, and selftolerance is established in the thymus during early development, mutated neoantigens
hold the potential to break self-tolerance and allow immune recognition of tumor
neoantigens. In fact, this finding let to Schreiber’s theory of immunoediting, suggesting
that Darwinian evolution is, again, at work in the development of cancer – only cells that
are able to avoid immune recognition survive the elimination phase of immunoediting,
and eventually outgrow following an equilibrium phase. Alternatively, or in addition to
7

immunoediting, tumors can shut down neoantigen reactive T cell attack by mechanisms
including MHC-I downregulation, production of immunosuppressive cytokines, physical
T cell exclusion, and induction of T cell exhaustion via augmented checkpoint
interactions such that the T cells are unable to exert immune selective pressure on the
tumor (Dunn et al. 2004; Dunn et al. 2002; Schreiber et al. 2011).
The concept of immune evasion and immunoediting is considered one of the hallmark
enabling characteristics of cancer, along with genomic instability and mutation. In fact,
the genomic mutation frequency in cancer correlates with better outcomes and better
response to immunotherapy, solidifying the concept that more mutations result in more
neoantigens and an increased likelihood for T cell mediated attack. Furthermore, there is
abundant evidence that an increased CD8 T cell infiltration in the TME results in better
overall survival in a number of different human cancers. Conversely, there is an inverse
relationship between macrophage infiltration and overall survival and response to
immunotherapy – more macrophages are associated with a poor prognosis. Below, we
discuss the biology of macrophages and the means by which they promote tumor
progression.

The role of macrophages in cancer

Macrophages are highly plastic cells, capable of adapting to diverse tissues and
environmental stimuli. The fact that monocytes/macrophages can extravasate, traffic, and
8

persist within diverse and hypoxic tissues, and have the potential to exert both proinflammatory and anti-inflammatory effects, makes them the perfect candidate immune
cell for tumors to recruit. Tumors actively recruit myeloid cells in the form of both
peripheral blood monocytes and neighboring normal tissue resident macrophages by the
production of chemokines (e.g. CCL2), growth factors (e.g. CSF-1), and other soluble
factors (Noy & Pollard 2014). As discussed above, cancer is elegantly defined by several
hallmarks described by Hanahan and Weinberg, which were updated in 2011 to include
inflammation, immune evasion, and metabolic reprogramming. Table 1.1 summarizes the
tumor promoting role of macrophages and provides examples of how each hallmark is
actively enabled or promoted by tumor associated macrophages.

Table 1.1: Methods of macrophage enablement of the Hallmarks of Cancer

Hanahan & Weinberg
Method of macrophage enablement
Hallmark of Cancer
Genomic instability

Release of reactive oxygen species
Secretion of proteases at tumor margin (i.e. metalloproteinases

Invasion and metastasis

and cysteine cathepsin proteases); establishment of the premetastatic niche

Sustained proliferation

Production of growth factors (i.e. EGF)

9

Limited cell death

Activation of anti-apoptotic genes (i.e. survival factors)

Enhanced angiogenesis

Secretion or activation of angiogenic factors (i.e. VEGF)
Release of immunosuppressive cytokines (i.e. secretion of IL-

Immune evasion

10, TGF-beta; Expression of immunosuppressive checkpoint
ligands and receptors (i.e. PDL-1 and SIRP-alpha)
Release of inflammatory mediators (IL1-alpha and IL1-beta),

Chronic inflammation

recruitment of inflammatory immune cells (via chemokine
production i.e. CCL5, CCL22)

Outside of the tumor microenvironment, macrophages are key orchestrators and
regulators of the innate immune system. Macrophages can be found in every tissue of the
body, where they can adapt unique phenotypes and serve specified functions (Haldar &
Murphy 2014). In the liver, macrophages adopt a Kupffer cell phenotype, upregulating
phagocytic capacity in order to actively patrol the blood flow for pathogens, senescent
erythrocytes, and apoptotic bodies (Nguyen-Lefebvre & Horuzsko 2015). In addition,
Kupffer cells break down hemoglobin into bilirubin and play a key role in iron
metabolism. In the spleen, splenic red zone macrophages are particularly well adapted at
the phagocytosis of senescent red cells and iron recycling. In the brain, macrophages
form microglial cells, capable of regulating neuronal synapse formation, axonal pruning,
and many other functions (Saijo & Glass 2011). In the lung, macrophages form alveolar
macrophages, particularly well adapted at the function of surfactant recycling and first
10

response to environmental pathogens, allergens, particulates, and toxins (Hussell & Bell
2014). Macrophages are particularly abundant in the submucosal lining of outward facing
tissues, such as the respiratory system, the gastrointestinal system, and the skin – where
they provide a key innate protective role in the form of phagocytosis and acute
inflammatory response. Together, these cells types (and many other known and unknown
macrophage subtypes) form the mononuclear phagocyte system, also known as the
reticuloendothelial system.
Despite their known role in the promotion of tumor progression, inflammation,
immunosuppression, invasion, and metastasis, macrophages also have anti-tumor
potential – phagocytic destruction of tumor cells, T cell recruitment, degradation of
fibrosis, reduction of angiogenesis, antigen presentation, and T cell stimulation.
Macrophages can adopt a broad spectrum of activation states in response to
environmental cues, cell-cell interactions, soluble factors, and metabolic factors. Though
an oversimplified approach to the highly complex potential of macrophage activation
states, the field has adopted the terms M1 (classically activated) and M2 (alternatively
activated) to represent the polar opposite ends of the macrophage activation spectrum.
M1 macrophages are associated with a pro-inflammatory, anti-tumor phenotype, in that
they upregulate co-stimulatory ligands, antigen processing and presentation genes, MHC
molecules, lymphocyte recruiting chemokines, and activating cytokines (e.g. interferons,
TNF-alpha, IL-12, IL1-b, others). M2 macrophages, on the other hand, are antiinflammatory, immunosuppressive, and pro-tumoral. M2 macrophages produce
immunosuppressive factors such as IL-10 and TGF-beta, upregulate checkpoint ligands
11

such as PDL-1, and promote the invasion, metastasis, fibrosis, and angiogenesis of
tumors. The terms M1 and M2 stem from the TH1 and TH2 type immune responses with
which they associate.
In table 1.2 we summarize and show examples of macrophage stimuli and the resulting
phenotype.
Table 1.2: Diverse inputs lead to variable macrophage activation states
Input

Receptor

Resulting Phenotype

Interferon-gamma (IFNg)

IFNGR1

Classically activated / M1

Lipopolysaccharide (LPS) TLR4 / CD14

Classically activated / M1

TNF-alpha (TNFa)

TNFR1

Classically activated / M1

Beta-glucan (b-glucan)

Dectin-1

Classically activated / M1

Interleukin-4 (IL-4)

IL4RA1

Alternatively activated / M2

Interleukin-13 (IL-13)

IL13RA1 / IL4RA1

Alternatively activated / M2

Interleukin-10 (IL-10)

IL10RA

Alternatively activated / M2

Apoptotic cell bodies

CD36, SRA,
MARCO, SR-B1,
CD68, MER, CD91,
LRP1, JMJD6

Alternatively activated / M2

Human macrophage phenotype and activation state, though oft over-simplified and
highly variable on epigenetic and transcriptomic levels, can be assessed by easily
detectable and measurable surface proteins that are upregulated or downregulated
depending on the stimuli to which the cell has been exposed. In table 1.3, we summarize
12

the common human macrophage surface markers used in flow cytometry and
immunohistochemistry:
Table 1.3: Common human macrophage markers and associated
function/phenotype

Marker

Function

Associated phenotype/marker
purpose

CD11B (ITGAM)

Adhesion/migration

Myeloid identity

CD14

LPS co-receptor

Myeloid identity

CD68 (macrosialin)

Scavenger/lectin/selectin
receptor

Myeloid identity

CD80 (B7-1)

Co-stimulatory ligand

Classical activation/M1 marker

CD86 (B7-2)

Co-stimulatory ligand

Classical activation/M1 marker

CD163

Scavenger receptor for
hemoglobin/haptoglobin

Alternative activation/M2 marker

CD206 (MRC1)

C-type lectin/mannose
receptor/PRR

Alternative activation/M2 marker

CD209 (DC-SIGN)

C-type lectin/PRR

Alternative activation/M2 marker

There is actively increasing interest in harnessing macrophage effector function for
cancer immunotherapy. Currently, most macrophage minded approaches can be split into
three categories: (i) depletion of immunosuppressive tumor associated macrophages, or
(ii) repolarization of suppressive macrophages to anti-tumor macrophages, or (iii)
enhanced tumor associated macrophage phagocytosis (Morrison 2016).
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In the below table 1.4 we review some of the foundational current pre-clinical and
clinical macrophage minded immunotherapeutic approaches for the treatment of cancer.

Table 1.4: Macrophage minded immuno-oncology approaches

Pharmacologic
category

Mechanism of action

Reference

Anti-CD47 monoclonal Blockade of the antiphagocytic CD47/SIRPa
antibody
interaction leads to enhanced
phagocytosis

(Weiskopf 2017;
Weiskopf et al. 2016;
Chao et al. 2010)

Anti-SIRPa
monoclonal antibody

Blockade of the antiphagocytic CD47/SIRPa
interaction leads to enhanced
phagocytosis

(Weiskopf et al. 2014; Liu
et al. 2016)

Anti-CSF1/CSF1R
monoclonal antibody

Reduction in the recruitment of
monocytes and maintenance of
tumor associated macrophages
by blocking the activity of the
macrophage colony
stimulating factor (M-CSF,
CSF-1) on the
monocyte/macrophage CSF1
receptor

(Cannarile et al. 2017;
Garcia et al. 2016; Ries et
al. 2014; Holmgaard et al.
2016; Ryder et al. 2013)

CSF1R small molecule
inhibitor

Reduction in the recruitment of (Butowski et al. 2016)
monocytes and maintenance of
tumor associated macrophages
by blocking the activity of the
macrophage colony
stimulating factor (M-CSF,
CSF-1) on the
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monocyte/macrophage CSF1
receptor
Anti-CD40 agonist
antibody

Activates resting antigen
presenting cells including
macrophages and dendritic
cells

(Beatty et al. 2011; Beatty
et al. 2017; Vonderheide
& Glennie 2013; Long et
al. 2016)

Induces the expression of
MHC class I and MHC class
II, as well as costimulatory
molecules and adhesion
molecules
Increases antigen presenting
cell derived cytokine
production
Reduction of tumor fibrosis
CCR2 antagonist

Reduction in the recruitment of (Nywening et al. 2016; An
monocytes to the tumor
et al. 2017; Schmall et al.
microenvironment by blocking 2015; Roblek et al. 2015)
the CCL2 chemokine from
binding to the monocyte CCR2
receptor, subsequently
resulting in fewer tumor
associated macrophages

CCL2 antagonist

Reduction in the recruitment of
monocytes to the tumor
microenvironment by blocking
the CCL2 chemokine from
binding to the monocyte CCR2
receptor, subsequently
resulting in fewer tumor
associated macrophages

CXCR1/CXCR2
antagonist

Reduction in the recruitment of (Colin W. Steele et al.
monocytes to the tumor
2016; Colin W Steele et
microenvironment by blocking al. 2016)
the monocyte CXCR1/CXCR2
chemokine receptors,
subsequently resulting in fewer
tumor associated macrophages
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(Qian, Li, Zhang,
Kitamura, Zhang,
Campion, E. a Kaiser, et
al. 2011; Popivanova et al.
2009; Wang et al. 2018)

JAK/STAT inhibitors

Reduced inflammatory and/or
immunosuppressive gene
expression in response to
cytokines including IL4
(STAT6), IL13 (STAT6), IL10
(STAT3), IL6 (STAT3)

(O’Shea et al. 2015; Li &
Watowich 2014)

Increased expression of M1
associated genes
Enhanced responsiveness to
chemotherapy and
immunotherapy
CXCL12/CXCR4
antagonist

Decrease in the recruitment of
monocytes/macrophages to the
tumor microenvironment

(Tseng et al. 2011)

Decreased macrophagederived angiogenic support
TIE2 antagonist

Inhibition of the Tie2 tyrosine
kinase receptor (expressed in
macrophage subsets and
endothelial cells) reduces
myeloid infiltration,
angiogenesis, and decreases
invasion/metastasis

(Forget et al. 2014;
Harney et al. 2017)

TLR ligands

Induction of classically
activated macrophage (M1)
genes in TAMs

(Whitmore et al. 2004;
Chang et al. 2014; Lee et
al. 2014)

Enhanced anti-tumor
properties
Enhanced antigen presenting
properties
Induction of type II interferon
and TNF-alpha
Anti-IL4/IL4R
antibody

Blockade of the cytokine IL4
from acting on the macrophage
IL4 receptor, thus preventing
or reducing M2 polarization
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(Bankaitis & Fingleton
2015)

Reduction in the macrophage
proliferative signal derived
from IL4 in the TME
Anti-IL6/Anti-IL6R
antibody

Reduced IL6 derived
inflammatory signaling and
JAK/STAT3 pathway
activation

(Caetano et al. 2016; Long
et al. 2017)

Enhanced responsiveness to
chemotherapy in pancreatic
ductal adenocarcinoma
Reduction of M2 TAMs and
myeloid-derived suppressor
cells
Trabectedin

Tetrahydroisoquinoline
alkaloid developed as a DNA
intercalating chemotherapeutic
drug

(Germano et al. 2013;
D’Incalci et al. 2014)

Monocyte/TAM depletion via
activation of caspase-8
dependent apoptosis in these
cells semi-selectively
Inhibition of the expression of
pro-inflammatory and proangiogenic genes such as IL-6,
CCL2, CXCL8, ANG-2, and
VEGF but not TNF-alpha
Zoledronic acid

Direct depletion of TAMs by
approximately 30-35%

(Green & Lipton 2010;
Hiroshima et al. 2014)

Decrease in MMP-9
(associated with invasion and
metastasis)
Enhancement of M1 associated
genes in TAMs
Class IIA HDAC
inhibitor

Epigenetic modulator leads to
the repolarization of M2
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(Guerriero et al. 2017)

TAMs toward an anti-tumor
M1 phenotype
Induces the recruitment and
differentiation of highly
phagocytic and stimulatory
macrophages within tumors
(example: TMP195)
PI3K-gamma inhibitor

Inhibition of PI3K-gamma
reduces PDK1, AKT1, and
TSC signaling and enhances
pro-inflammatory NFkB
mediated gene expression
changes and macrophage
activation

(Kaneda et al. 2016;
Zheng & Pollard 2016)

Macrophage engaging
bi-specific antibody

Crosslinking of tumor
associated antigens and
activating macrophage
receptors, such as CD16,
CD32, or CD64, leading to
phagocytic clearance of
targeted cells

(Wallace et al. 2001;
Wallace et al. 2000)

Tumor targeted
monoclonal antibody

Opsonization of tumor
(Braster et al. 2014;
associated antigens and
Weiskopf & Weissman
induction of antibody mediated 2015)
cellular phagocytosis by
activating macrophage Fc
receptors
The affinity for each class of
IgG and the various Fc
receptors varies and can be
enhanced by altering the
glycosylation pattern of the
IgG heavy chain

As of 2018, the most advanced approaches in this list (aside from traditional monoclonal
antibodies like rituximab and trastuzumab, which have a myriad of functions aside from
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macrophage activation) are inhibitors of CD47/SIRPa and CSF-1/CSF-1R. These
approaches are currently in clinical trials, and their efficacy in sentinel phase III trials
remains to be determined. Inhibitors of CD47/SIRPa are giving strong signals in the
contest of rituximab refractory lymphoma, but the publicly disclosed efficacy in solid
tumor trials is minimal. Notably, in the context of solid tumors, these pharmacological
agents mechanistically rely on the function of already M2 polarized tumor associated
macrophages, and the delivery of ex vivo activated and targeted cells is a logical next
step in the development of anti-tumor macrophages.

Chimeric Antigen Receptor (CAR) T cells
Overview
Current approaches to immunotherapy include vaccines, monoclonal antibodies,
inflammatory adjuvants, cytokines, oncolytic viruses, bispecific antibodies, and adoptive
cell therapy. The first cell therapies in the context of cancer, dating back to the 1980s,
consisted of either allogeneic lymphocyte transfers for leukemia or the infusion of tumor
infiltrating lymphocytes (TILs). TIL therapy is based on the premise that if neoantigen
reactive T cells were present in the cancer patient, they would likely exist within the
tumor microenvironment. Metastatic melanoma patients have had profound curative
responses to TIL therapy, though the majority of treated patients failed to respond to
treatment (Hinrichs & Rosenberg 2014).
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T cells, specifically alpha-beta T cells, naturally recognize short peptides in the context of
MHC-restricted presentation via the heterodimeric and diverse T cell receptor (TCR),
with self-reactive clones deleted through the processes of central and peripheral
tolerance. B cells, on the other hand, recognize surface bound and soluble antigens in a
non-MHC restricted fashion through the action of immunoglobulin receptors, which are
also highly diverse through the process of VDJ recombination and somatic
hypermutation. T cell specificity can be genetically manipulated through the exogenous
overexpression of either engineered TCR-alpha and TCR-beta genes, as is the case with
transgenic-TCR T cell therapy, or via the introduction of a chimeric antigen receptor
(CAR). The CAR is a fully man-made construct, coupling the extracellular non-MHC
restricted antigen specificity of the immunoglobulin or B-cell receptor, with the
intracellular signaling capacity of the TCR and TCR co-stimulatory receptors.
Structure
CARs are generated by genetically fusing the variable antigen recognition domain of
monoclonal antibodies – specifically the single chain variable fragment (scFv) – with a
hinge domain, a transmembrane domain, and one or more intracellular signaling domains.
The structural domains of the CAR, along with the function, tunable parameters, and
examples are summarized in Table 1.5.
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Table 1.5: CAR structural domains and function
Domain

Example(s)

Function

Parameters

Membrane
orientation

Targeting
domain

Monoclonal
antibody
derived
single chain
variable
fragment
(scFv)

Antigen
recognition

Affinity

Extracellular

Tethering
and
displaying
the targeting
domain

Length

Dimerization

DARPin
Centyrin
Nature
ligand
Hinge

CD8 Hinge
IgG4 Hinge

Transmembrane CD8 TM
(TM) domain
domain
IgG TM
domain
Co-stimulatory
domain

4-1BB
CD28
OX40

Extracellular

Flexibility
Dimerization

Connecting
Dimerization
the
extracellular Lipid raft
portion to the association
intracellular
portion

Membrane
spanning

Providing
signal 2 of
the T cell
activation
cascade

Intracellular

ICOS

Signaling pathway
and downstream
second messengers
Intensity of
activation

Metabolic
reprogramming
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Gene expression
profile
Stimulatory
domain

CD3-zeta
Fc-gamma

Providing
signal 1 of
the T cell
activation
cascade

Signaling pathway
and downstream
second messengers

Intracellular

Signaling strength
Induced effector
functions/cytokines

While scFv’s are the most common antigen binding domains used in CARs, alternative
non-antibody-based antigen recognition domains such as DARPins, ankyrin based
recognition motifs, have proven to also provide antigen specific T cell activation
(Plückthun 2015). Furthermore, natural receptors or ligands have been used as the
extracellular domain, allowing for natural affinity to the cognate ligand or receptor. The
importance of the affinity for each target is determined in an empirical fashion, as the
antigen density on tumor and normal tissue varies for each CAR target (Ellebrecht et al.
2016).
The hinge domain of the CAR serves a physical function to give length and flexibility to
the scFv. Commonly used hinges include the CD8a hinge and the IgG4 hinge. The
function and optimization of each scFv/hinge pair are determined empirically, and the
rules are not fully understood. There is evidence that IgG based hinges are subject to
reactivity with Fc receptors, leading to undesired effects (Hudecek et al. 2015). The hinge
also serves the purpose of determining the length of the CAR. There have been studies
demonstrating that there is an optimal length for the CAR/target cell interaction, and if
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the combined length of the CAR/target is too short or too long, the efficacy of T cell
activation is decreased (Kulemzin et al. 2017.).
The transmembrane domain provides the link between the extracellular and intracellular
regions of the CAR. The transmembrane domain is the least studied structural CAR
domain, and typically is acceptable as long as the CAR is expressed well on the cell
surface. Some transmembrane domains lead to better levels of CAR expression than
others, and the choice of transmembrane domain is determined empirically for every
CAR with a unique extracellular and intracellular domain. The choice of the scFv, hinge,
and transmembrane domain is also paramount to the inherent dimerization of the CAR
molecule and therefore the level of background tonic signaling, which is unfavorable as it
leads to the enhanced acquisition of an exhausted T cell phenotype (Long et al. 2015;
Gomes-Silva et al. 2017).
The fundamentally key portion of the CAR is the intracellular signaling and costimulatory signaling domains. Currently, all clinically utilized CAR constructs encode
the CD3-zeta primary CAR signaling domain. The co-stimulatory domain, on the other
hand, derives from either the 4-1BB receptor in Novartis’ Kymriah® or the CD28
receptor in Gilead’s Yescarta®. Studies have shown that the presence of an
immunoreceptor tyrosine-based activation motif (ITAM) is necessary for the activity of
CARs. Specifically, the ITAM tyrosine’s must be intact in order for downstream
signaling as they are the targets of CAR phosphorylation and activation. Previous studies
have shown that Fc-gamma based CARs are also effective in T cells (Eshhar et al. 1993;
Hwu et al. 1995; Gross & Eshhar 1992).
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The introduction of co-stimulatory domains from either 4-1BB or CD28 was the sentinel
discovery that led to the clinical success of CARs in human leukemia and lymphoma
patients. T cells require multiple signals for full and complete activation. The recognition
of MHC-peptide ligand through the TCR alone is insufficient – T cells must receive a
second signal through a co-stimulatory receptor/ligand pair in order to fully activate,
produce cytokines and effector molecules, proliferate, and avoid anergy. All CARs that
include co-stimulatory domains are referred to as second-generation CARs and have
enhanced activation, cytokine secretion, proliferation, killing, and persistence as
compared to first generation CARs. The choice of the co-stimulatory domain of the CAR
leads to differential in vitro and in vivo activity. CD28 co-stimulated CAR constructs
become activated more rapidly, have greater acute activity, upregulate exhaustion
markers, have reduced long term activity, have an increased effector memory phenotype,
and depend on glycolytic metabolism, as compared with 4-1BB co-stimulated CARs
(Kawalekar et al. 2016). 4-1BB CARs, on the other hand, demonstrate increased
persistence, decreased exhaustion, improved long term activity, an increase central
memory phenotype, and depend on oxidative metabolism, as compared to CD28 CARs
(Kawalekar et al. 2016). Direct head-to-head comparisons in the clinical setting of
diverse CAR constructs have not been performed. There have been many studies of novel
or diverse CAR co-stimulatory domains, such as OX40 and ICOS, and some have
combined two co-stimulatory domains to produce “third-generation” CARs (Hombach et
al. 2012; Guedan et al. 2014). The improvement in efficacy in third- versus secondgeneration CARs remains to be determined.
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Mechanism of action
Upon the recognition of antigen and dimerization by CARs on a CAR-T cell, the CD3zeta and co-stimulatory domains become phosphorylated and activated, leading to both
immediate and delayed effects on the T cell. In the immediate phase, T cells secrete preformed granules containing lethal molecules, notably perforin and granzyme B. Upon
release, perforin forms pores on the target cell’s plasma membrane via calciumdependent oligomerization. Perforin, as its name suggests, has the primary function of
forming pores, which allow the dysregulation of ion flux and, more importantly,
specifically allow the entry of pro-apoptotic granzyme proteins. Granzyme B is a
protease that specifically cleaves and activates pro-apoptotic caspases 8, 10, 3 and 7.
Furthermore, granzyme B can directly act on BID, Mcl-1, and potentially hundreds of
other substrates via its protease activity (Chowdhury & Lieberman 2008). Ultimately, the
combination of granzyme B and perforin leads to the rapid induction of target cell death.
Perforin and granzyme B are not the only methods by which CAR-T cells can induce
target cell death. CAR-T cells upregulate Fas-L, the ligand for the extrinsic apoptosis
receptor Fas, which is expressed by some but not all tumor cells. The interaction of Fas-L
with Fas leads to the trimerization of the Fas receptor, recruitment of intracellular death
domains and the formation of the death-inducing signaling complex, which ultimately
activates caspase 8 and causes target cell apoptosis. CAR mediated T cell activation
causes the induction of surface Fas ligand and is a direct mechanism for tumor killing.
However, T cells themselves express Fas receptor, and the fratricidal interaction of CART Fas-L with CAR-T Fas receptor is a mechanism of activation induced cell death
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(AICD) (Tschumi et al. 2018). Furthermore, active CAR-T cells upregulate and produce
TNFa, the ligand for the death receptor TRAIL, which is expressed on some but not all
tumor cells. The binding of soluble or surface bound TNFa to TRAIL induces another
form of extrinsic apoptosis, leading to again a caspase-8 mediated target cell death.
In addition to direct cytolytic killing of target cells, CAR-T cells produce a myriad of
cytokines, each of which has its own myriad of receptors and downstream functions.
Notably, CAR-T cells produce IL2, which serves to stimulate T cell proliferation and
activation, and IFN-gamma, which also modulates the T cell gene activity and gene
expression. CAR-T derived cytokines can directly impact the tumor cells and the tumor
microenvironment, having both positive and negative effects.
Lastly and importantly, CAR activation leads to the proliferation of CAR-T cells. Upon
seeing target, a proliferative signal leads to the rapid cell division of CAR-T cells,
allowing for the expansion of the biological drug in a disease-related fashion. In other
words, if there is a large tumor antigen burden, the number of CAR-T cells exponentially
rises. As the tumor is cleared and antigen burden is reduced, the number of CAR-T cells
dwindles – mimicking the reaction of natural T cells in an infectious response. As with
natural immunity, CAR-T cells can serve to promote the prolonged response to tumor and
prevention of relapse by inducing epitope spreading via lytic cell death and activation of
antigen presenting cells, by augmenting the activity of endogenously reactive T cells via
cytokines, and by the formation of long-lasting memory CAR-T cells, scavenging for
relapsed cells (June & Sadelain 2018).
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Efficacy in human clinical studies: Hematologic malignancy
CAR-T cells directed against CD19, a highly expressed B-cell restricted surface antigen,
are by far the most studied and clinically developed CAR-T cells worldwide. CD19 is
oft-said to be the perfect CAR target, as it is ubiquitously expressed in B cell malignancy,
is restricted to B cells, and is brightly expressed on the cell surface. Tisagenlecleucel-T,
also known as Kymriah®, was developed by Novartis and is currently indicated for
patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL)
that is refractory or in second or later relapse, and adult patients with relapsed or
refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy
including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade Bcell lymphoma and DLBCL arising from follicular lymphoma. Axicabtagene ciloleucel,
also known as Yescarta®, was developed by Kite and Gilead and is currently indicated
for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after
two or more lines of systemic therapy, including diffuse large B-cell lymphoma
(DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high
grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Neither of the
cell products are approved for central nervous system lymphoma.
In the registration trial of Tisagenlecleucel-T in relapsed/refractory B-cell acute
lymphoblastic leukemia in patients up to 25 years old, 68 patients were treated in a large
multi-center single arm trial called the ELIANA trial. Out of 63 evaluable patients, 83%
demonstrate a complete response (Maude et al. 2018; Mueller et al. 2018). This level of
response in relapsed/refractory leukemia was unprecedented. In the registration trial of
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Tisagenlecleucel-T in adult relapsed/refractory diffuse large B cell lymphoma, 68
patients were treated in the multi-center single arm JULIET trial. Of the 68 patients
evaluated, 50% demonstrated an overall response, and 32% demonstrated a complete
response. In the registration trial of Axicabtagene ciloleucel in relapsed/refractory large B
cell lymphoma, 101 patients were treated in a multi-center single-arm study. Of the 101
patients evaluated, 72% demonstrated an objective response and 51% demonstrate a
complete response (Neelapu et al. 2017). The median duration of response in this trial
was 9.2 months.
Targets, toxicities and mechanisms of resistance
As with all cancer therapies, CD19 directed CAR-T cells, though effective in otherwise
incurable patients, demonstrated significant expected and unexpected toxicity. The key
issue in the immunotherapy of human cancer is that almost all tumor associated antigens
are also expressed on normal tissues. In the below table 1.6, we summarize some of the
many CAR targets that have been pre-clinically and clinically evaluated and provide the
potential indications and the normal tissues on which each target is expressed.

Table 1.6: CAR targets, indications, and normal tissue expression
Target

Tumor
category

Potential
indications

Normal tissue
expression

Reference

BCMA

Hematologic

Multiple
myeloma

Plasmablasts

(Cho et al.
2018)

Acute myeloid
leukemia

Hematopoietic
stem cells

CD123

Hematologic

28

Plasma cells

(Gill, Tasian,
Ruella,
Shestova, Li,

Endothelial
cells
Myeloid
precursors

Porter, Carroll,
DanetDesnoyers, et
al. 2014)

Mature
myeloid cells
CD138

Hematologic

Multiple
myeloma

Plasma cells
Epithelial cells
Hepatic/GI
tissue

CD171/L1CA
M

Solid

Neuroblastoma
Cervical
carcinoma
Ovarian
carcinoma

Cerebral grey
matter

(Tian et al.
2017;
Palaiologou et
al. 2014)

(Hong et al.
2014)

Cerebellum
Pituitary gland

Bladder cancer

Peripheral
nerve

others

Kidney
Skin
Retina
Adrenal gland

CD19

Hematologic

B-cell acute
lymphoblastic
leukemia

Pro-B cell

B-cell chronic
lymphoblastic
leukemia

Naïve B-cell

Diffuse large B
cell lymphoma
Mantle cell
lymphoma
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Pre-B cell

Activated Bcell
Mature B-cell
Memory B-cell
Late
plasmablast

(Maude et al.
2015; Maude
et al. 2018;
Tasian &
Gardner 2015)

Follicular
lymphoma
CD20

Hematologic

Non-Hodgkin
lymphoma

Naïve B-cell
Activated Bcell

(Till et al.
2012; Y.
Wang et al.
2014)

Mature B-cell
Memory B-cell
CD22

Hematologic

B-cell acute
lymphoblastic
leukemia

Mature B-cell
and other Bcell subsets

(Haso et al.
2013; Long et
al. 2013)

CD30

Hematologic

Hodgkin’s
lymphoma

Activated Tcell

(Ramos et al.
2017; Di Stasi
et al. 2009;
Horie &
Watanabe
1998)

Activated Bcell
Activated NKcell
Subset of
activated
myeloid cells
CD33

Hematologic

Acute myeloid
leukemia

Hematopoietic
stem cells

(Kenderian et
al. 2015)

Monocytes
Macrophages
Microglial
cells
Neutrophils
Granulocytes
Myeloid
precursors
CD38

Hematologic

Acute myeloid
leukemia
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Hematopoietic
stem cells

(Drent et al.
2016; Yoshida
et al. 2016;

T cell leukemia

NK cells

Multiple
myeloma

Monocytes

B-cell chronic
lymphocytic
leukemia

Hartman et al.
2010)

Activated Tcells
Activated Bcells

CD5

Hematologic

T cell leukemia

T-cells

(Mamonkin et
al. 2015;
Raikar et al.
2018; Chen et
al. 2017)

CD70

Hematologic

Diffuse large B
cell lymphoma

Activated Tcell

Follicular
lymphoma

Activated Bcell

(Park et al.
2018; Shaffer
et al. 2011)

Hodgkin
lymphoma

Dendritic cells

Solid

Waldenstrom
macroglobulinem
ia
Multiple
myeloma
Renal cell
carcinoma
glioblastoma
Head and neck
squamous cell
carcinoma
CEA

Solid

Colorectal
carcinoma
Breast cancer
Liver cancer
31

Pulmonary
(Wang et al.
epithelial cells 2016; Katz et
(apical surface) al. 2015;
Burga et al.
Gastrointestina 2015)
l epithelial

Stomach cancer
Pancreatic ductal
adenocarcinoma
Ovarian cancer

cells (apical
surface)
Embryonic
tissue

Lung cancer
EGFR

Solid

Glioblastoma

Keratinocytes

Non-small cell
lung cancer

Gastrointestina
l tract

Metastatic
colorectal cancer

Renal system

(Caruso et al.
2016; Liu et
al. 2015)

Many other
carcinomas
EGFRvIII

Solid

Glioblastoma
multiforme

None

(Johnson et al.
2015; Choi et
al. 2017;
O’Rourke et
al. 2017)

EpCAM

Solid

Various
carcinomas

All normal
epithelial
tissue except:

(Deng et al.
2015; Ang et
al. 2017;
Schmelzer &
Reid 2008)

epidermal
keratinocytes

gastric parietal
cells

myoepithelial
cells

thymic cortical
epithelial cells
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hepatocytes
EphA2

Solid

Glioma
Non-small cell
lung cancer

FAP

Solid

Solid

GI tract

(Li et al. 2018;
Shi et al.
2018)

Esophageal
squamous cell
carcinoma

Kidney

Mesothelioma

Fibroblasts
(activated)

(Lo et al.
2015; L.-C. S.
Wang et al.
2014)

bronchial
epithelium

(Schutsky et
al. 2015;
Kandalaft et
al. 2012; Song
et al. 2016)

Many
carcinomas
FR-alpha

Epithelial
tissue

Ovarian cancer
Other carcinomas

Urinary system

renal tubules
choroid plexus
intestinal
brush-border
membranes
type-1 and
type-2
pneumocytes
of the lung
placental tissue
FR-beta

Hematologic

Acute myeloid
leukemia

Normal
myeloid
lineage cells

GD2

Solid

Neuroblastoma

Central
(Singh et al.
nervous system 2014; Prapa et
al. 2015; Louis
Peripheral
et al. 2011;
nerves
Heczey et al.
2014)
Skin
melanocytes
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(Lynn et al.
2015)

Glypican-3

Solid

Hepatocellular
carcinoma
Lung squamous
cell carcinoma

HER2

Solid

Breast cancer
Ovarian cancer
Gastric cancer

Lung
Liver
Female
reproductive
tissues
Pulmonary
tissue
Cardiac tissue

Glioblastoma
Esophageal
cancer
Sarcoma

(Baumhoer et
al. 2008; Li et
al. 2016; Gao
et al. 2014)

(Ahmed et al.
2015;
Priceman,
Tilakawardane
, et al. 2018;
Nellan et al.
2018; Feng et
al. 2018;
Lanitis et al.
2012)

Lung cancers
IL13Ra2

Solid

Glioma

Testis
Pituitary gland

Kappa Light
Chain

Hematologic

Multiple
myeloma

B cells
Plasma cells

(Brown et al.
2018; Kong et
al. 2012;
Brown et al.
2015)
(Ramos et al.
2016)

Non-Hodgkin
lymphoma
Chronic
lymphocytic
leukemia
Mesothelin

Solid

Mesothelioma
Ovarian cancer
Triple neg breast
cancer
Pancreatic cancer
Lung cancer
34

Mesothelial
cells

(Pastan &
Hassan 2014;
Adusumilli et
al. 2014;
Beatty et al.
2014; Zhao et
al. 2010)

Stomach cancer
Bile duct cancers
MUC1

PSCA

hematologic

Pancreatic cancer Glycosylation
pattern
Leukemias
dependent
tumor
specificity

(Posey,
Clausen, et al.
2016; Posey,
Schwab, et al.
2016; Maher
et al. 2016;
Steentoft et al.
2018)

Solid

Prostate cancer

Brain

bladder cancer

Stomach

renal cell
carcinoma

Placenta

(Priceman,
Gerdts, et al.
2018; Hillerdal
et al. 2014;
Abate-Daga et
al. 2014)

Solid

Kidney
Pancreas
Bladder

PSMA

Solid

Prostate cancer

Kidney
Proximal small
intestine
Salivary gland

ROR-1

Solid

Breast cancer

Hematologic

Non-small cell
lung cancer

B-cell
precursors
Adipocytes

Sarcomas

Pancreas

Mantle cell
lymphoma

Lung
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(Ghosh &
Heston 2004;
Kloss et al.
2018;
Junghans et al.
2016;
Zuccolotto et
al. 2014;
Santoro et al.
2015)
(Hudecek et al.
2010; Hudecek
et al. 2013;
Berger et al.
2015)

B-cell chronic
lymphocytic
leukemia
VEGFR-II

Solid

Melanoma
Renal cell
carcinoma

Endothelial
cells

(Chinnasamy
et al. 2010)

In the case of CD19 directed CAR-T cells, the antigen is restricted to the B cell lineage.
Expectedly, patients that received autologous anti-CD19 CAR-T therapy developed B
cell aplasia and increased susceptibility to infection. B-cell aplasia is a tolerable side
effect and can be overcome by providing patients with repeat infusion of pooled
intravenous immunoglobulins from human donors. This is currently part of the standard
treatment protocol. In addition to on-target off-tumor toxicity, CD19 CAR-T cells are
associated with cytokine release syndrome (CRS), a serious side effect caused by the high
level of pro-inflammatory cytokines produced by activated CAR-T cells at their peak
proliferation and activation state. Cytokine release syndrome leads to flu-like symptoms,
capillary leakage, hypoxia, and hypotension and requires intensive care management by
trained physicians. Studies have shown that IL-6, and its activity on myeloid cells bearing
IL-6 receptors, is a key mechanism of the syndrome and management with tocilizumab,
an anti-IL6R antibody, significantly reduces the severity of CRS.
CAR-T cells may also lead to unexpected toxicities. In the case of CD19 CARs,
neurotoxicity has been seen in a number of different centers, with diverse anti-CD19
trials and conditioning regimens. The mechanism of neurotoxicity is unclear and poorly
understood, but the symptoms are largely reversible. Given that each CAR is unique in its
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structure, unpredicted non-specific binding to proteins other than the target antigen is a
safety concern. It is very difficult to measure and predict the binding of CARs to proteins
other than the expected antigen in relevant pre-clinical models.
CAR-T cells in solid tumors: clinical efficacy and mechanisms of resistance
Despite the success of CD19 directed CAR-T cells in leukemia and lymphoma, the
efficacy of CAR-T cells in the solid tumor setting is currently minimal. There is a single
reported patient that received CAR-T cells targeted against the glioblastoma antigen
IL13RA2 that demonstrated a significant tumor regression (Brown et al. 2016). Several
trials of CAR-T cells against the well-established tumor antigen HER2 have been
conducted. A single case report of a patient with colorectal cancer metastatic to the lung
and liver treated with HER2 CAR-T cells described acute death (Morgan et al. 2010).
This patient received a significantly higher cell dose than what is believed to be
maximally tolerated, and numerous additional trials of HER2 CAR-T cells were
conducted without any significant toxicity. These trials, however, failed to show any
significant anti-tumor response. For example, a trial in which 19 patients with sarcoma
were treated with autologous anti-HER2 CAR T cells led to stable disease in 4 patients –
without any measurable tumor regression in any of the patients (Ahmed et al. 2015).
Anti-EGFRvIII CAR-T cells failed to lead to significant tumor regression in a
glioblastoma trial (Johnson et al. 2015). Overall, the response rate to CAR-T therapy in
the solid tumor setting has been close to zero regardless of target, histology, or CAR
design.

37

The exact mechanism by which solid tumors defend themselves against CAR-T mediated
destruction remains unclear, and several distinct mechanisms are likely. First, the
expression of solid tumor associated antigens is heterogenous throughout the primary and
metastatic tumors, allowing for the rapid outgrowth of target dim or target negative cells
via the action of evolutionary selection. Secondly, the tumor microenvironment of solid
tumors is metabolically harsh and hypoxic and is unfavorable to the high metabolic needs
of rapidly proliferating T cells. Thirdly, the tumor microenvironment is generally rich in
immunosuppressive factors such as IL-10, TGF-beta, and high levels of immune
checkpoint ligands such as PDL-1. Fourth, many solid tumors actively exclude T cell
trafficking and penetration via the development of fibrosis and the recruitment of tumor
associated macrophages which aid in restricting T cell entrance. In addition, tumors can
rapidly downregulate surface antigens in response to T cell pressure, in line with the
concept of immunoediting.
HER2 targeted therapy
In this thesis, we introduce and demonstrate the targeted anti-tumor potential of human
CAR macrophages. In particular, we focus on CAR macrophages directed against the
well-established tumor associated antigen HER2/neu. HER2 is encoded by the human
ERBB2 gene, a member of the epidermal growth factor receptor family. HER2 is found
to be amplified or over-expressed in approximately 30% of breast cancers and is
associated with an aggressive phenotype. Aside from breast cancer, HER2 is found to be
amplified on gastric cancers, sarcomas, lung cancers, pancreatic cancers, glioblastoma,
esophageal cancers, and other solid tumor types.
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Given the known role of HER2 in a myriad of solid tumors – particularly breast and
gastric carcinomas – several HER2 targeted therapies have been developed and are
currently FDA approved in the United States. Table 1.7 summarizes the currently
available HER2 targeted therapies, their mechanism of action, their clinical efficacy, and
their associated serious adverse events.

Table 1.7: FDA approved HER2 targeted therapies

Pharmacologic Description
agent

Mechanism of
action

Efficacy

Serious
adverse events

Trastuzumab
(Herceptin®)

Interference with
ligand dependent
and independent
HER2 signaling

Metastatic
breast cancer:

Decreased left
ventricular
ejection
fraction

Humanized
monoclonal
antibody
targeted to
the
extracellular
domain
(subdomain
IV) of HER2

Induction of
HER2
internalization or
down-regulation

Antibody
dependent
cellular
cytotoxicity

Antibody
dependent
cellular
phagocytosis
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7.2-month time
to progression
(trastuzumab +
chemotherapy)
vs. 4.5-month
time to
progression
(chemotherapy
alone)
Metastatic
gastric cancer:
13.5-month
median overall
survival
(trastuzumab +
chemotherapy)
vs. 11.0-month
median overall
survival
(chemotherapy
alone)

pulmonary
toxicity

infusion
reactions
febrile
neutropenia

Pertuzumab
(Perjeta®)

Humanized
monoclonal
antibody
specific for
the
extracellular
domain
(domain II)
of HER2

Interference with
ligand dependent
and independent
HER2 signaling

Induction of
HER2
internalization or
down-regulation

The
recognized
Antibody
epitope is
dependent
distinct from
cellular
trastuzumab
cytotoxicity
Used in
combination
with
trastuzumab

Adotrastuzumab
emtansine
(Kadcyla®)

an antibody
drug
conjugate of
trastuzumab
with
emtansine
(also called
cytotoxic
DM1)

Metastatic
breast cancer:
56.5-month
median overall
survival
(pertuzumab
plus
trastuzumab
plus docetaxel)
vs. 40.8-month
median overall
survival
(trastuzumab
plus docetaxel)

Decreased left
ventricular
ejection
fraction
pulmonary
toxicity
infusion
reactions
febrile
neutropenia
embryo-fetal
toxicity

Antibody
dependent
cellular
phagocytosis

Targeted delivery
of the
microtubule
inhibitor
emtansine to
HER2 positive
cells via
internalization of
the antibody-drug
conjugate
complex
Microtubule
disruption leads
to cell cycle
arrest and
apoptosis
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Metastatic
breast cancer:

Pulmonary
toxicity

30.9-month
median overall
survival (adotrastuzumab
emtansine) vs.
25.1-month
median overall
survival
(lapatinib plus
capecitabine)

Infusion
reactions
Hemorrhage
Thrombocytop
enia
Neurotoxicity

Ado-trastuzumab
emtansine retains
the other
mechanisms of
action of
trastuzumab
Neratinib
(Nerlynx®)

Small
molecule
tyrosine
kinase
inhibitor

Small molecule
kinase inhibitor
of EGFR, HER2,
and HER4
signaling
Irreversible
antagonist
Reduces receptor
autophosphorylat
ion
Reduces
downstream
MAPK and AKT
signaling

Adjuvant
treatment in
breast cancer:

Diarrhea

4.7% of
patients having
a disease
recurrence
(neratinib) vs.
7.5% of
patients having
a disease
recurrence
(placebo)

Embryo-fetal
toxicity

Metastatic
breast cancer:

Decreased left
ventricular
ejection
fraction

Hepatotoxicity

Leads to cell
cycle arrest and
apoptosis
Lapatinib
(Tykerb®)

Small
molecule
tyrosine
kinase
inhibitor

Small molecule
kinase inhibitor
of EGFR and
HER2 signaling
Reversible
antagonist
Reduces receptor
autophosphorylat
ion
Reduces
downstream
MAPK and AKT
signaling
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75-week
median overall
survival
(lapatinib plus
capecitabine)
vs. 65.9-week
median overall
survival
(capecitabine)

Hepatotoxicity
Diarrhea
Interstitial lung
disease
QT
prolongation
Cutaneous
reactions

Leads to cell
cycle arrest and
apoptosis

Embryo-fetal
toxicity

References:
(Cameron et al. 2008; Chan et al. 2016; Perez et al. 2017; Shah et al. 2017; Verma et al.
2012; Swain et al. 2015; Tolaney et al. 2015; Swain et al. 2013)
Aside from being amplified on HER2 positive solid tumor cells, HER2 is expressed at
lower levels on numerous normal tissues. In particular, HER2 is detected on cells of the
cardiovascular and pulmonary systems, which explains why the serious adverse events
associated with HER2 targeted therapies are cardiopulmonary in nature. Overall, the
currently available HER2 targeted therapies are not curative in metastatic solid tumors
and enhance overall survival by several months. HER2 is a strong candidate for adoptive
cellular therapy, though care must be taken to monitor patients for signs of
cardiopulmonary on-target off-tumor toxicity.

Macrophages in cell therapy
Activated monocyte derived macrophages were shown to have non-specific and low
potency anti-tumor activity in vitro against cancer cell lines. Based on these results,
researchers in the 1990s and early 2000s conducted numerous clinical trials in which
cancer patients were treated with autologous monocyte derived macrophages. These cells
were either infused as M0 non-activated macrophages or were pre-treated with M142

inducing stimuli IFN-gamma and LPS. Patients with various solid tumors were treated
with autologous macrophages injected either intraperitoneally, intravenously,
intrapleurally, intra-hepatic arterially, and intra-vesicularly. In all routes of
administration, autologous macrophages were safe but ineffective. Table 1.8 summarizes
the previous clinical experience with adoptively transferred human macrophages in
cancer.
Table 1.8: Previous experience with adoptively transferred macrophages in cancer
patients
Cell type,
activation
method

Route &
dose

Disease

Effect

PK/BD [1]

Reference

Leukapheresis
and
elutriation,
cultured 7
days, 18 h in
1000 U/mL
IFNγ

i.p., 3.5 ×
107
cells/dose,
weekly for
8 weeks

Colorectal
cancer with
peritoneal
metastasis

N/A

In-111
label, signal
stayed
within the
peritoneum
for 5 days,
blood
peaked at
9% at 48 h,
no transfer
to other
organs

(Stevenso
n et al.
1987)

Leukapheresis
and
elutriation,
cultured 7
days, 18 h in
200 U/mL
IFNγ

i.v. or i.p.,
1–4 × 108

Systemic
metastasis
(i.v.),
Peritoneal
metastasis
(i.p.)

Only
therapeutic
effect: 2/7
disappearance
of peritoneal
ascites

N/A

(Andreese
n et al.
1990)

cells/dose,
escalating
every 2
weeks
(i.v.) or
weekly
(i.p.)
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MΦ Activated
Killer (MAK)
Leukapheresis
and
elutriation,
cultured 6d in
500 U/mL
GMCSF and
18 h in 166
U/mL IFNγ

i.v., 0.1–5
× 108
cells/dose,

dose from
107–
109/dose

IFNγ prior to
cell collection

N/A

In-111
label,
greatest
signal in
lungs at 24
h, migrating
to liver and
spleen at 72
h,
decreasing
thereafter

(Faradji,
Bohbot,
SchmittGoguel, et
al. 1991)

Peritoneal
carcinomatosi
s (ovarian,
pancreatic,
gastric,
appendiceal)

No
therapeutic
response.
Increase of
IL-1, IL-6 and
TNFα in
peritoneal
cavity

In-111
label, signal
stayed in
abdominal
cavity for
up to 7
days, no
signal in
lungs, liver
or spleen,
0.5% in
blood

(Faradji,
Bohbot,
Frost, et
al. 1991)

Colorectal or
stomach
cancer with
liver
metastasis

No
therapeutic
response

In-111, 1 h:
18% lung,
56% liver, 7
d: 12%

(Hennema
nn et al.
1995)

Colorectal
cancer

No
therapeutic
response.
11/14

escalating
weekly

MAK,
i.p.,
Activated with Escalating
mifamurtide
weekly

MAK,
patients dosed
with 50 μg/m2

Non-smallcell lung
cancer

i.v. via
hepatic
artery, 1–
10 × 108
cells/day,
3
sequential
days,
depending
on cell

lung, 43%
liver

recovery
from
patient
MAK

i.v., 1 ×
109
cells/dose
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N/A

(Eymard
et al.
1996)

weekly for
6 weeks
MAK,
activated with
1 ng/mL LPS
for 30 min.
Patients dosed
with 2–4 ng/kg
LPS prior to
cell collection

i.v., 3 ×
106–4
×108

MAK

MAK

showed
progression,
3/14 stabilized
Cancer
(Colorectal,
renal,
pancreatic,
melanoma or
NSC lung)

Increase in
N/A
TNFα and IL6
by 40×, 1/9
patients with
stable disease
(b25%
growth), 8/9
showed
progression

(B
Henneman
n et al.
1998)

i.p.
3x109/dos
e, 3 doses
over 2
weeks

Metastatic
renal
carcinoma

Transitory
stabilization
(n=8) or
partial
regression
(n=1) in 9 of
15 patients

In-111
label, at
72h, lung
(6%), liver
(24%),
spleen
(11%),
blood (3%)

(Lesimple
et al. n.d.)

i.v. or i.p.,
1-2 × 109
in

Metastatic
ovarian
carcinoma

N/A

In-111 or
(Ritchie et
PET F18al. 2007)
FDG. i.v.:
Accumulati
on in lungs
at 4 h
(10%), at 24
h, liver
(50%) and
spleen (4%).
Accumulati
on in tumor
in 4/10
patients i.p.:
Accumulati
on in tumor
in 4/6
patients

Recurrence
occurred
signiﬁcantly

N/A

cells/dose,
escalating
weekly for
7 weeks

single
dose

MAK

Intravesica Superﬁcial
Bladder
lly, 2 ×
Cancer
45

(BaronBodo et al.
2005;

108/dose,
weekly for
6 weeks

Ixmyelocel-T
– bone
marrow
aspirate
enriched for
regenerative
macrophages
and
mesenchymal
stromal cells
by a
proprietary
process

Local
injection
to multiple
sites in
affected
heart or
limb, 30300 ×
106/dose

Dilated
cardiomyopat
hy or critical
limb
ischemia

less frequent
with standard
treatment than
with cells
(12% vs.
38%; p b
0.001)

Burger et
al. 2010)

Reduced
N/A
major adverse
cardiovascular
events (14%
treated, 56%
control),
reduced time
to ﬁrst
occurrence of
treatment
failure

(Henry et
al. 2014;
Powell et
al. 2012)

- Table modified from: (Lee et al. 2016)
- i.p.=intraperitoneal; i.v.=intravenous
- MAK = macrophage activated killer cells
[1] PK/BD=pharmacodynamics/biodistribution

Taken together, the results from the past experience with adoptive transfer of human
macrophages in cancer provided evidence that macrophages have the potential to traffic
into solid tumors and metastatic sites, are well tolerated, but fail to recognize and attack
the tumor. Retrospectively, without the provision of an opsonizing agent, the initiation of
the phagocytic program against tumor cells was unlikely to occur in these trials. These
studies set the precedent for genetically engineered macrophage cell therapy, and suggest
that if properly engineered, CAR macrophages have the potential to traffic to solid
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tumors and productively engage tumor-associated antigens to debulk tumors via the
process of phagocytosis.
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CHAPTER 2: Chimeric antigen receptors redirect human macrophage phagocytosis
of cancer cells

Abstract
The non-MHC restricted redirection of T cell and natural killer (NK) cell activity via the
introduction of chimeric antigen receptors leads to efficient targeted tumor recognition.
Both T and NK cell effector function can be activated via CAR signaling. In this chapter,
we hypothesize that macrophage phagocytosis of tumor cells can be redirected via the
introduction of CD3-zeta and Fc-gamma intracellular domain-based CARs. Using in vitro
microscopy based phagocytosis assays, we demonstrate the targeted and ITAMdependent activity of CARs in the THP-1 human macrophage model. Macrophage
phagocytosis was effective against all three antigens tested – CD19, mesothelin, and
HER2. The activity of anti-CD19 CARs in THP-1 macrophages was augmented by
pharmacologic and genetic ablation of the anti-phagocytic CD47/SIRPa interaction. The
data presented in this chapter demonstrated the ability to genetically rewire phagocytosis
and set the groundwork for translation of the CAR macrophage concept into primary
human macrophages.

Introduction
Macrophages are sentinel cells of the immune system where they act as a crucial
component of the immune system’s first line of defense. The primary effector mechanism
by which macrophages engage bacterial cells, fungal cells, apoptotic cells, and opsonized
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cells is via the mechanism of phagocytosis. The phagocytic program requires the
recognition of pro-phagocytic signals by a pro-phagocytic receptor, the absence of an
anti-phagocytic signal acting on an anti-phagocytic-receptor, and the engagement of a
complex signaling cascade that leads to the directional reorganization of the cellular
cytoskeleton that allows the macrophage to engulf a large body. Macrophages naturally
express a myriad of pro-phagocytic receptors that allow for the recognition and
phagocytosis of infectious particles. For instance, the dectin-1 receptor recognizes betaglucan on the surface of Candida albicans, a pathogenic yeast, and leads to the direct
phagocytosis of these fungal cells. The lipopolysaccharide (LPS) receptor TLR4, with its
co-receptor CD14, leads to the direct recognition and phagocytosis of gram-negative
bacteria. Interestingly, recognition of LPS or beta-glucan not only triggers phagocytosis
of the pathogen but induces a pro-inflammatory activated macrophage phenotype, which
serves to trigger a first-responder alarm to the local tissue and immune system that an
immune response should be initiated.
The pro-phagocytic receptors that recognize conserved patterns that are present and
fundamental to the biology of pathogens (i.e. LPS, beta-glucan, flagellin) are broadly
referred to as pattern recognition receptors. While not all pattern recognition receptors are
phagocytic, all non-opsonic phagocytic receptors are pattern recognition receptors (PRR).
The phagocytosis of live cells without PRR-mediated clearance is dependent on soluble
intermediates, notably antibodies and complement. Antibody mediated cellular
phagocytosis (ADCP) is the process by which antibody opsonized target cells are
recognized by macrophage activating Fc receptors and subsequently phagocytosed.
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Apoptotic cells, unlike live cells, are directly recognized by macrophage apoptotic/cellcorpse recognition receptors and internalized through the process of efferocytosis – a
term describing the non-inflammatory clearance of apoptotic cells and cell corpses. The
efferocytosis of apoptotic cells occurs via the recognition of conserved apoptotic features,
such as extracellular exposure of phosphatidylserine, upregulation of extracellular
calreticulin, or, in the case of old erythrocytes, reduced levels of the anti-phagocytic
ligand CD47.
The interaction of human macrophage pro-phagocytic Fc receptors with the Fc domain of
immunoglobulins leads to the phosphorylation of the intracellular domain of the Fc
receptor or associated signaling molecules. Fc-gamma-RII, for instance, has an
intracellular immunoreceptor tyrosine-based activating motif (ITAM) which allows the
receptor to directly induce a phagocytic signaling program upon Fc recognition and
receptor clusterization. Other Fc receptors require recruitment of the common Fc gamma
chain, Fc-epsilon-RI, an intracellular adaptor and signaling protein, to provide the
necessary ITAM in order to induce the phagocytic program. Antibody mediated
phagocytosis can be augmented through the action of complement – a series of zymogens
with pro-inflammatory properties, with activated forms of certain complement proteins
capable of directly inducing phagocytosis by signaling through the complement receptors
CR1, CR3, or CR4 (van Lookeren Campagne et al. 2007).
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In the early development of CAR-T cells, Fc-espilon-R1, frequently referred to as
“gamma-chain” or the “common Fc gamma chain”, was the first CAR intracellular
domain utilized. The common gamma chain does not naturally get expressed in T-cells,
but was nevertheless capable of inducing T cell activation (Eshhar et al. 1993; Annenkov
et al. 1998; Hwu et al. 1995).
Mechanistically, the likely mechanism by which the Fc gamma chain induces T cell
activation is by mimicking the properties of CD247, the zeta chain of the CD3/TCR
complex. FcERI and CD3-zeta are highly similar in both sequence and in structure,
suggesting that though not identical, they have the potential to be replaceable in the
context of a CAR. We hypothesized that CARs, which are capable of inducing the
activation of T cells and NK cells in a non-MHC restricted fashion, may induce the
targeted phagocytosis of target bearing cells. In particular, we hypothesized that CD3zeta or Fc-gamma intracellular domain-based CARs can induce the phagocytosis of
cognate-antigen expressing target tumor cells.
Significant research over the past two decades has proven that the ubiquitously expressed
cell surface protein, CD47, serves as a “do-not-eat-me” signal to prevent phagocytosis of
self-cells (Oldenborg et al. 2001; Oldenborg et al. 2000; Willingham et al. 2012). CD47
is downregulated on aging erythrocytes to enhance their uptake by macrophages and is
upregulated on tumor cells to decrease their uptake by macrophages. CD47 exerts its
inhibitory action on macrophage phagocytosis via a direct interaction with the SIRPa
receptor. SIRPa is an inhibitory signal that bears an immunoreceptor tyrosine-based
inhibitory motif (ITIM) that leads to the dephosphorylation of ITAM bearing activators
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such as FcERI and Fc-gamma-RII. Multiple studies have shown that inhibition of the
CD47/SIRPa interaction between macrophages and target tumor cells leads to the
augmented phagocytosis of antibody-opsonized targets (Weiskopf 2017; Weiskopf et al.
2016; Weiskopf & Weissman 2015; Weiskopf et al. 2014; Alvey et al. 2017; Chao et al.
2010). Accordingly, we hypothesized that the blockade or genetic ablation of either
CD47 or SIRPa may lead to the enhanced activity of CAR mediated phagocytosis.
In this chapter, we demonstrate the fundamental concept that CARs are active in human
macrophages. Throughout this chapter we utilize the human myeloid cell line THP-1, a
leukemic cell line commonly used as a model for human macrophage biology (Tsuchiya
et al. 1980; Lund et al. 2016). We chose to test our hypothesis using the THP-1 model
because primary human macrophages are difficult to transfect and transduce, and the
identification of an effective gene delivery method in primary macrophages was the
subject of the second aim and second chapter of this thesis. The data within this chapter
demonstrates the concept that CD3-zeta and Fc-gamma chain-based CARs can induce the
phagocytosis of cognate antigen expressing tumor cells, without any phagocytosis of
target negative cells. This process requires an active intracellular ITAM bearing signaling
motif, and mimics the complex signaling that occurs during antibody dependent cellular
phagocytosis (ADCP). We show that THP-1 CAR macrophage phagocytosis is
augmented with the blockade of the CD47/SIRPa axis, and provide a groundwork for the
translation of this concept into primary human cells.
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Results
To model the potential for CAR-mediated redirection of macrophage phagocytosis, we
first used an anti-CD19 CAR in the human macrophage THP-1 cell line. We used a firstgeneration CAR encoding the CD3z intracellular domain (CAR19z), which has
significant sequence and structural homology to the Fc common g-chain, FceRI-g, a
canonical signaling molecule for ADCP in macrophages. We measured the phagocytic
potential of macrophages expressing an intact (CAR19z) or a truncated CAR
(CAR19Dz), lacking the CD3z intracellular domain (Figure 2.1). CAR19z but neither
CAR19Dz nor control untransduced (UTD) macrophages phagocytosed antigen-bearing
tumor cells in vitro (Figure 2.2A). Furthermore, CAR19z macrophages selectively
phagocytosed CD19+ but not CD19- tumor cells (Figure 2.2B), demonstrating that CAR
– antigen binding is integral to drive redirected macrophage phagocytosis. CAR
macrophage phagocytosis was an active process requiring Syk, non-muscle myosin IIA,
and actin polymerization, similarly to Fc receptor mediated ADCP, as demonstrated by
the inhibition of CAR activity upon pre-treatment with R406, blebbistatin, or
cytochalasin D, respectively (Figure 2.2C). The phagocytic activity of anti-CD19 CARs
against CD19+ targets was equivalent in macrophages expressing CD3z and Fcg based
CARs (Figure 2.3A), and the signaling of both gamma and zeta CARs was dependent on
Syk, as demonstrated by inhibition of CAR-mediated phagocytosis with the Syk inhibitor
R406 (Figure 2.3B). Furthermore, the specific lysis of CD19+ target cells at an effector
to target ratio of ten to one, after 48 hours of co-culture, was equivalent between gamma
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and zeta-based CAR constructs (Figure 2.3C). All subsequent experiments were
therefore performed using CD3z as the primary CAR intracellular domain. CARmediated macrophage phagocytosis was confirmed via live cell video microscopy against
antigen bearing and control tumor cells and by imaging flow cytometry (Figure 2.4A).
The behavior of a single CAR macrophage was tracked over time and key steps of the
phagocytic process are demonstrated (Figure 2.4B). CAR macrophages were capable of
polyphagocytosis, defined as the ability to engulf two or more target cells at once
(representative images, Figure 2.4C). Having shown that anti-CD19 CARs can redirect
macrophage phagocytosis, we sought to demonstrate that CAR macrophages can also be
targeted toward solid tumor associated antigens. We therefore introduced CARs against
mesothelin and HER2, utilizing singe chain variable fragments (scFvs) derived from
antibody clones SS1 and 4D5, respectively, and demonstrated phagocytic activity against
target cells expressing the appropriate cognate antigens (Figure 2.4D). Together these
data demonstrated that CD3z-based CARs can direct the phagocytic activity of human
THP-1 macrophages and provided support for subsequent efforts to translate this
platform to primary human macrophages.
Furthermore, to test whether CAR mediated phagocytosis is regulated by the same
mechanisms as Fc receptor mediated ADCP, we sought to test whether the CD47/SIRPa
interaction has an inhibitory effect on CAR19-zeta mediated phagocytosis. There was an
anti-CD47 and anti-SIRPa dose-dependent increase in the phagocytic activity of CAR19,
but not UTD, macrophages against target bearing tumor cells (Figure 2.5). This data
suggested that blocking either the ligand or the receptor is sufficient for antagonizing the
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inhibitory CD47/SIRPa axis, and that CARs are also potentially subject to SIRPa
mediated regulation. To test whether the additive phagocytic activity in the presence of
CD47 / SIRPa blockade is due to additional non-specific opsonization or is genuinely a
result of a lack of SIRPa activity, we compared the activity of a CD47 binding and
blocking clone (B6H12) to the activity of a CD47 binding but non-blocking clone (2D3).
The anti-CD47 2D3 monoclonal antibody binds to an epitope on the extracellular domain
of CD47 that does not interfere with SIRPa, unlike the blocking B6H12 clone. The
additive phagocytic activity was only seen with B6H12 and SIRPa blocking clone
SE5A5, but not with 2D3 (Figure 2.6).
To further validate the impact of antibody mediated blockade of CD47/SIRPa on CARmediated phagocytosis, we genetically ablated SIRPa on THP-1 macrophages using the
CRISPR/Cas9 system. We designed and in vitro transcribed three anti-SIRPa guide RNA
constructs and tested their ability to knock out SIRPa. Only one guide of the three –
Guide 2 – was capable of inducing measurable SIRPa knockout one-week post
electroporation of the Cas9-gRNA ribonuclear protein complex (Figure 2.7A). The
SIRPa negative cells were sorted for purity and used as effector cells in phagocytosis
assays. To validate the impact of the knockout, CAR19z or SIRPaKO-CAR19z THP1
macrophages were used as effectors in phagocytosis assays in the absence or presence of
anti-SIRPa blocking antibody. SIRPa KO led to the same level of phagocytic
enhancement as anti-SIRPa blocking antibody, and the addition of anti-SIRPa antibody to
SIRPa KO cells did not further enhance phagocytosis, suggesting that both the antibody
and knockout were specific (Figure 2.7B).
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Discussion
In conclusion, we show in this chapter the following fundamental concept: CARs are
active in macrophages. More importantly, we show that phagocytosis is rewireable. In
addition to the evolutionarily-obtained methods of phagocytosis via antibody receptors,
complement receptors, pattern recognition receptors, and efferocytosis receptors, we
show that the coupling of single chain variable fragment derived antigen recognition
domains to ITAM-bearing intracellular domains allows for the genetic manipulation of
the phagocytic process.
Furthermore, the data within this chapter demonstrates that CAR mediated activity in a
human macrophage model requires active CAR mediated signaling. The signaling of both
CD3-zeta and Fc-gamma based CARs led to targeted phagocytosis, sparing target
negative cells. Inhibitors of three distinct stages of the phagocytosis program – actin
polymerization, non-muscle myosin IIa mediated force generation, and Syk
phosphorylation – led to the ablation of CAR activity, suggesting that CARs activate the
internal machinery of ADCP signaling. We show that the concept of CAR mediated
phagocytosis is modifiable – as CARs against CD19, mesothelin, and HER2 were all
active against cells displaying the appropriate cognate antigens.
Given that CD47/SIRPa inhibits the activity of Fc receptor mediated phagocytosis, we
tested the impact of this regulatory axis on CAR activity. The pharmacologic and genetic
inhibition of CD47/SIRPa led to increased phagocytic activity by CAR19-zeta THP1
macrophages, suggesting that there is potential synergy in combining CAR macrophages
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with CD47 or SIRPa inhibitors. However, the importance of CD47/SIRPa in THP-1 cells,
which are not primary cells, may or may not be equally relevant in primary human
monocyte derived macrophages. Furthermore, given the known importance of the
distance between macrophage and target for phagocytosis (Bakalar et al. 2018), whether
or not this synergy will hold true for all CARs and all targets remains to be determined.
One can envision a scenario in which a long target or very short target could physically
preclude CD47 from binding to SIRPa and regulating phagocytosis.
Lastly, the success of CAR-T cells was largely due to the discovery and development of
co-stimulatory domains that augmented anti-tumor activity, cytokine release,
proliferation, phenotype, persistence, and other T cell characteristics. The CARs utilized
in this chapter and thesis are all “1st-generation” CARs – meaning there is no costimulatory domain included. The incorporation of co-stimulatory domains, alternative
signaling domains, and multiplexed signaling domains is the subject of future research.

Materials and Methods
Cell lines.
The THP-1, SKOV3, K562, MDA-468, CRL-2351, HTB-20, HTB-85, CRL-5803, CRL5822, CRL-1555, HTB-131, HTB-20, and CRL-1902 cell lines were purchased from
American Type Culture Collection (ATCC). Cells were culture in RPMI media with 10%
fetal bovine serum, penicillin, streptomycin, 1x Glutamax, and 1x HEPES unless
otherwise recommended by ATCC. All cell lines were transduced with a lentiviral vector
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co-encoding click beetle green (CBG) luciferase and green florescent protein (GFP)
under an EF1a promoter, separated by a P2A sequence. Transduced target cell lines were
FACS sorted for 100% GFP positivity prior to use as targets in vitro and in vivo. THP-1
cells were lentivirally transduced, FACS sorted, and maintained in liquid culture. CAR
expression and purity was routinely validated.

Plasmid construction and virus.
For lentivirus production, CAR constructs were cloned into the third generation pTRPE
lentiviral backbone using standard molecular biology techniques. All CAR constructs
utilized a CD8 leader sequence, (GGGGS)3 linker, CD8 hinge, and CD8 transmembrane
domain and were expressed under the control of an EF1a promoter. Lentivirus was
packaged in HEK293 cells and purified/concentrated as described previously(Gill,
Tasian, Ruella, Shestova, Li, Porter, Carroll, Danet-desnoyers, et al. 2014). In indicated
experiments, Vpx was incorporated into lentivirus at the packaging stage as previously
described(Bobadilla et al. 2013). Cell lines were transduced with lentivirus MOI 3-5
unless otherwise noted. For replication deficient adenovirus production, anti-HER2 CAR
was cloned into the pShuttle transfer plasmid using Xba-I and Sal-I, and subsequently
cloned into pAd5f35 using I-Ceu I and PI-Sce I. All cloning steps were validated by
restriction enzyme digest and sequencing. pAd5f35 is first generation E1/E3 deleted
adenoviral backbone. Ad5f35-CAR-HER2-z was generated, expanded, concentrated, and
purified using standard techniques in 293 cells by the Baylor Vector Development
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Laboratory. All adenoviral batches were verified negative for replication competent
adenovirus and passed sterility and endotoxin analysis. Adenoviral titer was determined
using Adeno-X Rapid Titer Kit (Clontech, USA) and validated by functional transgene
expression in human macrophages. An MOI of 1000 PFU/cell was used unless otherwise
stated.
Microscopy.
Microscopy based phagocytosis assay:
Control or CAR-expressing monomeric red fluorescent protein positive (mRFP+) THP1
cells were plated at 7.5x104 per well in 48 well plates and differentiated with 1ng/mL
phorbol 12-myristate 13-acetate (PMA) in RPMI with 10% FBS for 48 hours. Following
differentiation, PMA was washed out with media and 7.5x104 control or target GFP+
K562 tumor cells were added and co-cultured for 4 hours at 37°C. After 4 hours, tumor
cells (non-adherent) were washed out and the plate was imaged for mRFP and GFP
fluorescence. The average number of phagocytic events in three random fields of view
per well were averaged, in triplicate wells, on a 10x field of view. Cells were imaged
using an EVOS FL Auto 2 Imaging System (ThermoFisher Scientific, AMAFD2000).
Data represent the mean +/- standard error of triplicate wells. Statistical significance was
calculated via t-test.

Live video imaging microscopy:
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3.0x105 CAR or control mRFP+ THP-1 cells were differentiated as above in 6 well
plates and co-cultured with 3.0x105 control or target GFP+ K562 cells for 16-24 hours in
an incubated 37°C live imaging chamber and imaged ever 30-120 seconds for mRFP and
GFP using the EVOS FL Auto 2 Live Imaging System (ThermoFisher, USA) using the
10x lens.
Image cytometry.
Control or CAR mRFP+ THP-1s were differentiated and co-cultured with CD19+GFP+
K562 target cells as described above. After 4-hour co-culture, cells were washed and
harvested with trypsin-EDTA and stained with L/D aqua for viability. Imaging cytometry
was performed on Amnis ImageStreamX (EMD Millipore, Germany). Cells were gated
for mRFP+GFP+ double-positive events and the phagocytosis-identification algorithm
(Amnis ImageStreamX) was applied, which identifies GFP signal within an mRFP
positive event.
CD47/SIRPa inhibition and knockout experiments.
Control or CAR-expressing monomeric red fluorescent protein positive (mRFP+) THP1
cells were plated at 7.5x104 per well in 48 well plates and differentiated with 1ng/mL
phorbol 12-myristate 13-acetate (PMA) in RPMI with 10% FBS for 48 hours. Following
differentiation, PMA was washed out with media and the blocking CD47 antibody clone
B6H12, the non-blocking anti-CD47 clone 2D3, or the anti-SIRPa clone SE5A5 were
added in RPMI 10% FBS media for 30 minutes prior to the addition of 7.5x104 control or
target GFP+ K562 tumor cells were added and co-cultured for 4 hours at 37°C. After 4
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hours, tumor cells (non-adherent) were washed out and the plate was imaged for mRFP
and GFP fluorescence. The average number of phagocytic events in three random fields
of view per well were averaged, in triplicate wells, on a 10x field of view. Cells were
imaged using an EVOS FL Auto 2 Imaging System (ThermoFisher Scientific,
AMAFD2000). Data represent the mean +/- standard error of triplicate wells. Statistical
significance was calculated via t-test.
In vitro transcribed guide RNA’s, designed with the Benchling tool, were cloned,
transcribed, and purified following the manufacturer’s protocol of the GeneArt Precision
gRNA Synthesis Kit (ThermoFisher Scientific, A29377). In vitro transcribed guide RNA
was pre-incubated with S.p.Cas9 protein in vitro to form the Cas9:gRNA ribonuclear
protein complex, which was subsequently electroporated into THP-1 cells using a BTX
ECM 830 square wave electroporation system (BTX). Knockout efficiency was assessed
5-7 days post electroporation using surface SIRPa analysis with FACS. SIRPa negative
THP-1 cells were serially FACS sorted for purity and were used for functional assays.
Statistics.
Statistical analysis was performed in Prism 6.0 (GraphPad, Inc). Each figure legend
denotes the statistical test used. Error bars indicate standard error of the mean unless
otherwise indicated. ANOVA multiple comparison p-values were generated using
Tukey’s multiple comparisons test. All t-tests were two-sided. * indicates p<0.05, **
indicates p<0.01, *** indicates p<0.001, and **** indicates p<0.0001.
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Figures
Figure 2.1: CAR19 constructs used in THP-1 macrophages

Figure 2.1:
(A.) Constructs utilized in lentiviral vectors to express CAR-19 variants in THP-1 cells
(left). Both constructs were expressed downstream of an EF1A promoter.
(B.) Representative FACS plot of CAR19 expression (post-sort) in mRFP+ THP-1 cells
(right). The red population represents the control untransduced (UTD) THP-1
macrophages and the blue population represents the CAR-19 THP-1 macrophages post
sort.
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Figure 2.2: CAR19 THP-1 macrophage phagocytosis of CD19+ targets

Figure 2.2:
(A): In vitro microscopy based phagocytosis assays by indicated THP-1 macrophages
against CD19+ K562 target cells. Data represent the mean +/- standard error (SEM) of
triplicate wells. Statistical significance was calculated via one-way ANOVA with
multiple comparisons (1b) or two-sided t-test (1c) , **p<0.01.
(B): In vitro microscopy based phagocytosis of CD19+ or control CD19- K562 target
cells by CAR19z+ THP-1 macrophages. Data represent the mean +/- standard error
(SEM) of triplicate wells. Statistical significance was calculated via one-way ANOVA
with multiple comparisons (1b) or two-sided t-test (1c) , **p<0.01.
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(C): CAR19z+ THP-1 macrophages were pre-treated with media, cytochalasin-D (actin
polymerization inhibitor), blebbistatin (non-muscle myosin IIa inhibitor), or R406 (Syk
inhibitor) prior to the phagocytosis assay. Data represent the mean +/- SEM of triplicate
wells. Statistical significance was calculated via ANOVA with multiple comparisons,
****p<0.0001.

Figure 2.3: Comparison of CD3-zeta and Fc-gamma chain CARs

Figure 2.3:
(A): In vitro microscopy based phagocytosis assays by CAR19-zeta or CAR19-gamma
expressing THP-1 macrophages against CD19+ K562 target cells. Data represent the
mean +/- standard error (SEM) of triplicate wells. Statistical significance was calculated
via two-sided t-test **p<0.01.
(B): In vitro microscopy based phagocytosis assays by CAR19-zeta or CAR19-gamma
expressing THP-1 macrophages against CD19+ K562 target cells that were pre-treated
with R406 (Syk inhibitor).
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(C): Luciferase-based killing assay of CD19+K562 cells by UTD, CAR-19g, or CAR-19z
THP-1 macrophages (E:T=10:1;48hrs). Data represent the mean +/- SEM of triplicate
wells. Statistical significance was calculated via ANOVA with multiple comparisons,
***p<0.001; ns=non-significant.

Figure 2.4: Visualization of phagocytosis and validation of solid tumor targets

Figure 2.4:
(A): Imaging cytometry of UTD or CAR19z mRFP+ THP-1 macrophages after coculture with GFP+ CD19+ K562 target cells.
(B): Key steps of the CAR-19z THP-1 macrophage phagocytosis during a 24-hour live
cell fluorescent microscopy analysis.
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(C): Representative image of poly-phagocytic CAR19z THP-1 macrophages from 4-hour
co-culture at a 1:1 effector to target ratio.
(D): In vitro microscopy based phagocytosis of UTD or CAR-meso-z THP-1
macrophages of mesothelin+ K562 cells. Data is represented as mean +/- SEM. Statistical
significance was calculated via t-test. ****p<0.0001; **p<0.01.
(E): In vitro microscopy based phagocytosis of UTD or CAR-HER2-z of HER2+ K562
cells. Data is represented as mean +/- SEM. Statistical significance was calculated via ttest. ****p<0.0001; **p<0.01.

Figure 2.5: CD47/SIRPa inhibition augments CAR19 phagocytosis
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Figure 2.5:
(A): In vitro microscopy based phagocytosis of CD19+ K562 target cells by control (Wt)
or CAR19-zeta THP-1 macrophages in the presence of increasing quantities of a CD47
blocking monoclonal antibody.
(B): In vitro microscopy based phagocytosis of CD19+ K562 target cells by control (Wt)
or CAR19-zeta THP-1 macrophages in the presence of increasing quantities of a SIRPa
blocking monoclonal antibody.

Figure 2.6: CD47/SIRPa inhibition only enhances CAR-mediated phagocytosis of
target-bearing cells
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Figure 2.6:
(A): In vitro microscopy based phagocytosis of CD19+ K562 target cells by CAR19-zeta
THP-1 macrophages in the presence of increasing quantities of a CD47 blocking
monoclonal antibody, a control non-blocking CD47 monoclonal antibody, or a SIRPa
blocking antibody.
(B): In vitro microscopy based phagocytosis of control CD19(-) K562 target cells by
CAR19-zeta THP-1 macrophages in the presence of increasing quantities of a CD47
blocking monoclonal antibody or a SIRPa blocking antibody.
Figure 2.7: SIRPa KO CAR19 THP-1 macrophages display enhances phagocytosis
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Figure 2.7:
(A): Evaluation of three anti-SIRPa CRISPR guide RNAs or a negative control EMX
target guide RNA by FACS analysis of surface SIRPa expression.
(B): Post-sort expression and purity of CAR19(+) THP-1 macrophages that are control
(blue) or SIRPa KO using CRISPR Guide 2 (red).
(C): In vitro microscopy based phagocytosis of CD19(+) K562 tumor cells by CAR-19 or
CAR19 SIRPa KO THP-1 macrophages in the absence or presence of 10ug/mL antiSIRPa monoclonal antibody.
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CHAPTER 3: Primary human macrophages are efficiently transduced to express
CAR using Ad5f35 and demonstrate targeted anti-tumor activity

Abstract
The genetic manipulation of primary human monocytes, macrophages, and dendritic cells
is a known challenge in the field. In this chapter, we assess physical and viral methods of
the genetic manipulation of primary human monocyte derived macrophages and show
that the chimeric fiber adenoviral vector Ad5f35 is efficient in the transduction of
primary human macrophages. Furthermore, we utilize this vector to engineer primary
human macrophages with CD3-zeta based anti-HER2 CARs and test their phagocytic and
tumor killing specificity and potency. The activity of anti-HER2 CAR macrophages
required a moderate-to-high level of target HER2 surface expression to trigger activity.
Finally, we test the activity of primary human HER2 CAR macrophages in mouse
xenograft models of human HER2 positive ovarian cancer and demonstrate that with both
intraperitoneal and intravenous administration a single dose of human anti-HER2 CAR
macrophages prolongs overall survival.
Introduction
In chapter 2, we show the potential for CAR mediated phagocytosis using the THP-1 cell
line model of human macrophages. In order to validate the potential of the CAR
macrophage approach, we sought to genetically engineer primary human macrophages
with CAR. This brought upon us the fundamental issue of genetically engineering
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primary human macrophages. Previous studies have shown that macrophages are difficult
to engineer with retroviral and lentiviral vectors. In addition, chemical and physical
approaches to macrophage transfection are either largely inefficient, transient kinetically,
or induce high-level toxicity to the macrophage population. In this chapter we assess
multiple methods of genetic alteration of human macrophages. In particular, we focus on
monocyte derived macrophages which are the ex vivo differentiated progeny of
circulating CD14 cells. Specifically, the cells used in this chapter are classical
monocytes, as non-classical CD16+ CD14- monocytes are lost in the selection process.
We chose to use peripheral blood CD14+ monocytes because this is the largest potential
source of human macrophages. Alternatively, tissue macrophages, peritoneal
macrophages, or CD34+ hematopoietic stem cell derived cells would need to be used.
We further evaluate the potential role of primary human anti-HER2 CAR macrophages as
a therapeutic approach to the cell therapy of solid tumors. Chimeric antigen receptor T
cells have failed to show significant efficacy in several clinical trials targeting HER2 in
sarcoma and other solid tumors. There has famously been a single case of HER2 CAR-T
cell mediated fatal toxicity, though this patient likely received a toxic dose, as several
dozen patients treated in follow on studies did not experience marked toxicity. We chose
HER2 as the target of choice for proof-of-concept because of the known normal tissue
expression, the prevalence of this tumor associate antigen in many solid tumors where
there is a medical need, and the known ability of macrophages to phagocytose HER2+
cells via the action of anti-HER2 monoclonal antibodies.
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Previous studies of adoptively transferred autologous monocyte-derived macrophages in
solid tumors failed to demonstrate efficacy, though were well tolerated and did not induce
any notable adverse reactions. Without the introduction of a CAR, these cells were likely
unable to recognize tumor antigens and thus unable to initiate a phagocytic program. In
this chapter we test the potential for primary human anti-HER2 CAR macrophages to
phagocytose target bearing tumor cells, to kill various tumor targets, we assess the
dependence of CAR activity on antigen density and test the outcome of treating mice
xenografted with human tumors with human CAR macrophages.
Results
We generated primary human macrophages by differentiating human CD14+ monocytes
derived from the peripheral blood of normal donors using recombinant human GM-CSF
for 7 days (Figure 3.1A) (B. Hennemann et al. 1998; Hennemann et al. 1997). Normal
human donor apheresis product was subject to elutriation to deplete platelets,
erythrocytes, and lymphocytes. The relative abundance of lymphocytes, granulocytes,
and monocytes in Elutra fractions 3, 4, and 5 were measured by FACS and quantified
using a Beckman Coulter Counter. The monocyte rich fractions were subject to CD14+
selection using Miltenyi MACS CD14+ isolation beads. The selection purity was
measured by FACS and is showing in Figure 3.2B. Following selection, monocytes were
seeded into GMP cell differentiation bags (Miltenyi) in RPMI with 10% FBS, Glutamax,
and antibiotics with recombinant human GM-CSF to induce the monocyte-tomacrophage differentiation program. Cells were grown for seven days then harvested and
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used for assays or cryopreserved. The day-seven macrophage purity was >95%, with the
most significant contaminant immune cell being the neutrophil (Figure 3.2C).

Since transduction of primary human monocytes and macrophages is challenging (unlike
with the THP-1 cell line), we first tested the potential for macrophages to express CAR
via direct electroporation of in vitro transcribed anti-HER2 CAR. Both primary human
monocytes (undifferentiated CD14+ cells) and seven-day differentiation monocytederived-macrophages (with GM-CSF) were efficiently transected with an optimized RNA
electroporation program. The monocytes and macrophages expressed >70% CAR on
their surface (Figure 3.2A and Figure 3.2B). Given the transient nature of mRNA, we
tested the persistence of expression of RNA-CAR and found that RNA-CAR persists for
only approximately 5 days after electroporation, despite the lack of proliferation of the
terminally differentiated myeloid cells (Figure 3.2C). Given the short-term transfection
with in vitro transcribed CAR mRNA, we then tested a broad array of integrating and
non-integrating viral vectors including lentivirus, Vpx-modified lentivirus (Bobadilla et
al. 2013), a panel of AAV serotypes, and the modified chimeric fiber adenoviral vector
Ad5f35 (Nilsson et al. 2004). Vpx is an HIV-2/SIV derived protein that binds to
SAMHD1 and targets it for E3-ubiquitin mediated degradation (Romani & Cohen 2012).
SAMHD1 is an enzyme that actively depleted dNTPs, which serves to inhibit retroviral
infection as dNTPs are required for the key step of the retroviral infection process –
reverse transcription (Ballana & Esté 2015). Previous studies have shown that
incorporation of Vpx into HIV-1 based lentiviral vectors enhance the transduction
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efficiency of human myeloid cells (Bobadilla et al. 2013; Moyes et al. 2017). We selected
Ad5f35 in the panel of viral vectors because of the differential expression on human
macrophages of the Ad5 and Ad5f35 docking receptors, CXADR and CD46, respectively
(Figure 3.3). Our data showed minimal transduction with a broad panel of AAV
serotypes, ineffective transduction with VSV-G pseudotyped lentivirus, and improved yet
still relatively low-level transduction with Vpx-LV. Given the low transduction
efficiency of standard third generation lentiviral and AAV vectors (data not shown), and
the high multiplicity-of-infection (MOI) and viral volumes required for Vpx-lentivirus,
we chose to pursue Ad5f35 further (Figure 3.4). We engineered a CD3z-based antiHER2 CAR into an Ad5f35 backbone, and demonstrated the production of CARencoding vector, capable of transducing human macrophages at a high rate of efficiency
(Figure 3.5). We proceeded to validate the efficacy of this transduction method utilizing
Ad5f35 on macrophages derived from ten human donors and demonstrated
reproducibility across all ten donors with an ~70% CAR transduction efficiency (Figure
3.6). The resultant primary human anti-HER2 CAR macrophages demonstrated antigenspecific phagocytosis (Figure 3.7A). Furthermore, anti-HER2 CAR macrophages
achieved dose-dependent killing of several HER2high cancer cell lines in vitro (Figure
3.7B). The level of CAR expression directly correlated with the MOI of Ad5f35 used
during transduction (Figure 3.8A). In order to demonstrate the requirement of CAR for
phagocytic activity, we sought to demonstrate a correlation between CAR expression and
phagocytosis. We found that there was a direct correlation between phagocytosis of
HER2+ SKOV3 cells and the percentage of CAR positive macrophages (Figure 3.8B). In
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order to validate that the 4-hour phagocytic readout via FACS was a meaningful assay,
we correlated the level of phagocytosis as readout by FCS with a non-biased specific
lysis luciferase-based killing assay and saw a strong correlation, suggesting that
phagocytosis was leading to tumor death (Figure 3.8C).
We sought to demonstrate a dose-response association between antigen density and
phagocytic activity by electroporating a HER2negative cell line with increasing amounts of
in vitro transcribed HER2 mRNA and measuring phagocytic activity (Figure 3.9A). We
confirmed this using a panel of human cancer cell lines with graded expression of HER2
and demonstrated a clear correlation between antigen density and phagocytic activity
(Figure 3.9B), with minimal activity against antigen dim targets.
A major advantage to the adoptive transfer of macrophages is their potential for
accumulation in solid tumors. Previous studies have demonstrated that autologous
monocyte derived macrophages, upon intravenous infusion, localize at sites of primary
and metastatic disease (Faradji, Bohbot, Frost, et al. 1991; Lesimple et al. n.d.). A variety
of chemoattractant molecules are involved in myeloid cell trafficking, and studies have
shown that the chemokine CCL2 and its receptor CCR2 is of particular importance (Qian,
Li, Zhang, Kitamura, Zhang, Campion, E. A. Kaiser, et al. 2011). In order to test the
ability of human macrophages to traffic to SKOV3 tumors, we established an imaging
based biodistribution assay by engrafting GFP/luciferase labeled SKOV3 into NOD scid
yc

-/-

hIL3-hGMCSF-hSCF (NSGS) mice via subcutaneous injection and systemically

injecting macrophages pre-labeled with an intracellular dye with an infrared spectrum.
Tumors were grown until large, palpable, and visible for 3-4 weeks and macrophages
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were injected either IV or intra-tumorally. Five days post administration, mice were
subject to live whole-body imaging, followed by euthanasia, organ harvest and imaging.
Macrophages trafficked to subcutaneous tumor after systemic administration (Figure
3.10A). Terminal organ harvest and fluorescent imaging revealed the presence of
macrophages in lung, spleen, liver, and tumor. Importantly, aside from the tumor, the
liver seemed to be the major organ in which macrophages accumulated (Figure 3.10B
and Figure 3.10C). The presence of anti-HER2 CAR did not have any significant impact
on the trafficking pattern of macrophages in NSGS mice. A fundamental shortfall of this
model is that the non-SKOV3 derived tumor stroma secreted chemokines, the tumor
microenvironment, and the pattern of normal tissue HER2 expression in NSGS mice is
not reflective of human patients.
We next tested the in vivo anti-tumor activity of CAR macrophages using two distinct
models and routes of administration. The immunodeficient triple transgenic mouse strain
NOD scid yc-/- hIL3-hGMCSF-hSCF (NSGS) was used for all in vivo xenograft
experiments(Wunderlich et al. 2010). In the first model, NSGS mice were injected
intraperitoneally (IP) with luciferase-expressing SKOV3, a HER2high human ovarian
cancer cell line, and treated 2-4 hours later with a single IP injection of phosphate
buffered saline (PBS), UTD macrophages as a control for non-specific anti-tumor effects,
or anti-HER2 CAR macrophages (CAR) (Figure 3.11A). CAR, but not UTD
macrophages, led to marked tumor regression in the majority of treated mice as
demonstrated by serial bioluminescent imaging over 100 days (Figure 3.11B). The
treatment was not associated with significant toxicity as demonstrated by body weights
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(Figure 3.11C) and led to significantly improved overall survival in the CAR treatment
group (median survival 96 (CAR) vs. 38 days (UTD), p<0.0001)(Figure 3.11D). In the
second approach, we modeled metastatic disease by injecting SKOV3 intravenously (IV)
and allowing 7 days for engraftment. Mice then received a single IV injection of PBS,
macrophages transduced with empty Ad5f35 vector (Empty), or anti-HER2 CAR
macrophages (Figure 3.12A). CAR-treated mice demonstrated a marked reduction in
tumor burden (Figure 3.12B and Figure 3.11C). Though all mice eventually progressed,
a single infusion of CAR macrophages led to a prolongation of overall survival (median
survival 88.5 (CAR) vs. 63 days (Empty), p=0.0047) (Figure 3.12D). Collectively, these
results demonstrate that CAR macrophages can be efficiently generated from human
peripheral blood derived monocytes to affect targeted anti-tumor activity in vitro and in
murine xenograft models.

Discussion
In this chapter, we extend our findings from Chapter 2 into primary human macrophages.
These findings represent a significant advance on the concept as the ability to efficiently
transduce primary human macrophages served as a barrier to advancement in the field of
genetically engineered macrophage cell therapy. We identify the chimeric fiber
adenoviral vector, Ad5f35, which has tropism toward CD46, as a highly effective gene
transfer approach for primary human macrophages. Logically, human macrophages from
all donors tested expressed CD46 on their cell surface. We show that Ad5f35 is superior
in potency and level of gene expression to a myriad of adeno-associated virus serotypes,
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VSV-G pseudotyped HIV-1 based lentiviral vectors, and lentiviral vectors encapsulated
the Vpx protein to aid in transduction efficiency. Furthermore, though physical
electroporation of in vitro CAR mRNA was highly efficient, the persistence of RNACAR was transient. In ten human donors tested, the transduction efficiency of an antiHER2 CAR with Ad5f35 was approximately 70%.
Peripheral blood monocyte derived macrophages are terminally differentiated cells, so
the choice of a high titer and high quantity vector is necessary to achieve translational
potential with these cells. The average human apheresis product contains approximately
3x10^9 monocytes. Unlike with CAR-T cells, where a relatively small number of cells
(~1x10^8) is transduced and then expanded, all ~3x10^9 monocyte derived macrophages
need to be transduced in bulk. Ad5f35 is a high titer virus (~2x10^11 PFU/mL) and can
be scaled up to large viral production volumes and is thus a uniquely appropriate viral
vector for the generation of primary human monocyte derived CAR macrophages. In
addition, the viral vector has key impact on macrophage activation status and phenotype,
which will be described in Chapter 3.
We show that CD3-zeta CARs are effective in inducing the phagocytic program in
primary human macrophages, and that the results in the THP-1 model are representative
of primary human macrophages. Anti-HER2 CAR macrophages phagocytosed HER2+
SKOV3 tumor cells but not HER2 negative control cells. In this chapter, we chose to
focus on HER2 as the target antigen of choice to demonstrate proof-of-concept primary
CAR macrophage activity. HER2 is a well validated target with multiple targeted
therapeutics available on the market with proven efficacy in metastatic breast and gastric
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cancer. Overall, the impact of HER2 targeted therapy on overall survival in metastatic
solid tumors is marginal. Importantly, given the history of HER2 as a biomarker of
aggressive breast cancer and a target for commonly prescribed therapeutics like
trastuzumab, the normal tissue expression of HER2 is well studied and understood.
Unlike with other novel solid tumor associated surface antigens, the expected toxicity
with HER2 directed therapy is understood, with cardiac and pulmonary risks being the
most significant concerns. In order to address the potential risk of anti-HER2 trastuzumab
scFv based CAR macrophages to HER2 positive but dim cells, we performed HER2
titration assays and determined phagocytic activity. We show that when HER2 dim
cancer cell lines or HER2 negative cells with low levels of induced HER2 are used as
targets for phagocytosis assays, they are not eaten. These results suggest that there is a
threshold minimum for triggering of CAR signaling in macrophages and serve as a
potential positive sign for the safety profile of this approach. However, these in vitro
models are merely reductionist models and the potential for on-target off-tumor toxicity
must be carefully monitored and studied in clinical trials.
We show in this chapter that anti-HER2 primary human CAR macrophages, but not
untransduced negative control macrophages, are capable of killing target bearing tumor
cells in vitro in a dose-dependent manner. Furthermore, we provided proof-of-concept in
a murine xenograft model of human ovarian cancer, demonstrating the anti-tumor
efficacy of anti-HER2 CAR macrophages in a relevant disease model. In these
experiments, mice were treated with a single dose of the CAR engineered macrophages.
The persistence of human macrophages in mice and specifically in these experiments is
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unclear. Repeat dosing may lead to deeper and/or more persistent responses. Importantly,
the animal model in which efficacy was tested is the NSGS mouse – a genetically
engineered immunodeficient strain. Therefore, any efficacy seen in these experiments
stemmed directly from CAR macrophage mediated phagocytosis and killing of tumor.
The absence of the adaptive immune system in these mice did not offer the opportunity
for macrophage mediated antigen presentation and T cell stimulation, which would
potentially induce deeper response through the process of epitope spreading.
Identification of the appropriate models in which to test this hypothesis is the subject of
future research.
Materials and Methods
Cell lines.
The THP-1, SKOV3, K562, MDA-468, CRL-2351, HTB-20, HTB-85, CRL-5803, CRL5822, CRL-1555, HTB-131, HTB-20, and CRL-1902 cell lines were purchased from
American Type Culture Collection (ATCC). Cells were culture in RPMI media with 10%
fetal bovine serum, penicillin, streptomycin, 1x Glutamax, and 1x HEPES unless
otherwise recommended by ATCC. All cell lines were transduced with a lentiviral vector
co-encoding click beetle green (CBG) luciferase and green florescent protein (GFP)
under an EF1a promoter, separated by a P2A sequence. Transduced target cell lines were
FACS sorted for 100% GFP positivity prior to use as targets in vitro and in vivo. THP-1
cells were lentivirally transduced, FACS sorted, and maintained in liquid culture. CAR
expression and purity was routinely validated.
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Plasmid construction and virus.
For lentivirus production, CAR constructs were cloned into the third generation pTRPE
lentiviral backbone using standard molecular biology techniques. All CAR constructs
utilized a CD8 leader sequence, (GGGGS)3 linker, CD8 hinge, and CD8 transmembrane
domain and were expressed under the control of an EF1a promoter. Lentivirus was
packaged in HEK293 cells and purified/concentrated as described previously(Gill,
Tasian, Ruella, Shestova, Li, Porter, Carroll, Danet-desnoyers, et al. 2014). In indicated
experiments, Vpx was incorporated into lentivirus at the packaging stage as previously
described(Bobadilla et al. 2013). Cell lines were transduced with lentivirus MOI 3-5
unless otherwise noted. For replication deficient adenovirus production, anti-HER2 CAR
was cloned into the pShuttle transfer plasmid using Xba-I and Sal-I, and subsequently
cloned into pAd5f35 using I-Ceu I and PI-Sce I. All cloning steps were validated by
restriction enzyme digest and sequencing. pAd5f35 is first generation E1/E3 deleted
adenoviral backbone. Ad5f35-CAR-HER2-z was generated, expanded, concentrated, and
purified using standard techniques in 293 cells by the Baylor Vector Development
Laboratory. All adenoviral batches were verified negative for replication competent
adenovirus and passed sterility and endotoxin analysis. Adenoviral titer was determined
using Adeno-X Rapid Titer Kit (Clontech, USA) and validated by functional transgene
expression in human macrophages. A MOI of 1000 PFU/cell was used unless otherwise
stated.
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Animal studies.
All mouse studies were conducted in accordance with national guidelines for the humane
treatment of animals and were approved by the Institutional Animal Care and Use
Committee (IACUC) at the University of Pennsylvania. Schemas of the utilized xenograft
models are shown in detail in the first panel of each relevant figure. NOD/SCID Il2rg-/hIL3-hGMCSF-hSF (NSG-SM3 or NSGS) mice originally obtained from Jackson
Laboratories were purchased and bred by the Stem Cell and Xenograft Core at the
University of Pennsylvania. Cells (SKOV3 tumor cells, human macrophages, or human
T-cells) were injected in 200-300uL PBS for both IP and IV tail vein injections. IV
injections of human macrophages were split into consecutive injections to attain the
target dose. Bioluminescent imaging was performed at least weekly using an IVIS
Spectrum (Perkin Elmer, USA) and analysis as performed using LivingImage v4.3.1
(Caliper LifeSciences). Mice were weighed weekly and were subject to routine veterinary
assessment for signs of overt illness. Animals were euthanized at experimental
termination or when predetermined IACUC rodent health endpoints were reached.
Flow cytometry.
Primary human macrophages were tested for CAR-HER2 expression using a two-step
staining protocol: human HER2/ ERBB2 Protein-His tag (Sino Biological Inc, 10004H08H-100) primary stain followed by Human TruStain FcX (Biolegend, 422302) and
Anti-His Tag APC (R&D Systems, IC050A) secondary stain. TruStain FcX (Biolegend,
422302) was always used for FACS staining of monocytes, macrophages, or monocytic
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cell lines expressing Fc receptors. Macrophage purity was tested using the following
panel: Anti-CD11b PE (Biolegend, 301306), Anti-CD14 BV711 (Biolegend, 301838),
Anti-CD3 FITC (eBioscience, 11-0038-42), Anti-CD19 PE-CY7 (eBioscience, 25-019842), Anti-CD66b PerCP-CY5.5 (Biolegend, 305108), Anti-CD56 BV605 (Biolegend,
318334), and Live/Dead Fixable Aqua (L/D aqua) Dead Cell Stain Kit (ThermoFisher,
L34957). The same panel was used for testing the monocyte purity post CD14 MACS
selection, prior to seeding for differentiation. M1/M2 markers on primary human
macrophages were detected with the following panel: Anti-CD11B PE (Biolegend,
301306), Anti-CD80 BV605 (Biolegend, 305225), Anti-CD86 BV711 (Biolegend,
305440), Anti CD206 BV421 (Biolegend, 321126), Anti CD163 APC-CY7 (Biolegend,
333622), anti HLA-DR BV785 (Biolegend, 307642), Anti-HLA ABC PE/CY7
(Biolegend, 311430) and Live/Dead Fixable Aqua Dead Cell Stain Kit. CD46 expression
was detected with Anti-CD46 APC (Biolegend, 352405) and CXADR was detected with
Anti-CAR PE (EMD Millipore, FCMAB418PE-I). Appropriate fluorescence matched
isotype controls were acquired from Biolegend. Surface HER2 was detected using AntiHuman CD340/HER2 APC (Biolegend, 324408). Flow cytometry data were acquired on
a BD Fortessa with HTS (BD Biosciences, USA), and analyzed with FlowJo X10
(FlowJo, LLC).
FACS based phagocytosis assay.
1x105 UTD or CAR-HER2-z human monocyte derived macrophages (48 hours post
transduction) were co-cultured with media (Mac Alone), 1x105 GFP+ MDA-468 cells
(HER2-) or 1x105 GFP+ SKOV3 (HER2+) target cells for 3-4 hours at 37°C in triplicate.
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Following co-culture, cells were harvested with Accutase (Innovate Cell Technologies,
Inc., USA), stained with Anti-CD11b APC-CY7 (Biolegend, 301342) and analyzed via
FACS using a BD Fortessa (Beckton Dickinson, New Jersey). The percent of GFP+
events within the CD11b+ population was plotted as percentage phagocytosis. Data are
represented as mean +/- standard error of triplicate wells. Statistical significance between
CAR-HER2-z and UTD was calculated using ANOVA with multiple comparisons;
****p<0.0001, ns = non-significant.

Primary human macrophages and T-cells.
Normal donor apheresis was either performed at the hematology unit at the Hospital of
the University of Pennsylvania under an IRB approved protocol through the Human
Immunology Core of the University of Pennsylvania or were acquired and shipped fresh
from HemaCare (HemaCare Corporation, CA, USA). Apheresis derived leukopacs were
subject to elutriation using an Elutra Cell Separation System (Terumo BCT) to reduce
erythrocytes, platelets, lymphocytes, and granulocytes. Monocyte enriched fractions were
pooled and subjected to MACS CD14 positive selection (Miltenyi) per manufacturer’s
instruction. The pre-selection and post-selection (positive and negative fraction) purity
was tested using flow cytometry. Selected CD14 monocytes were seeded in Cell
Differentiation Bags (Miltenyi) in RPMI with 10% FBS, penicillin, streptomycin, 1x
glutamax, 1x HEPES, and 10ng/mL recombinant human GM-CSF (Peprotech, 300-03)
for 7 days. Differentiation was monitored by light microscopy. Adenovirus was added on
84

day 5 at an MOI of 1x103 based on plaque-forming unit (PFU) titer. Differentiated
macrophages were harvested at day 7 and tested for CAR expression, differentiation, and
macrophage purity by FACS. For smaller scale experiments macrophages were plated
directly in tissue-culture treated well-plates or flasks and transduced at an MOI of 1000
PFU directly in well plates or flasks. CD3 selected T-cells were provided by the
University of Pennsylvania Human Immunology Core and were expanded/transduced as
previously described.
In vitro cytotoxicity assay.
CBG/GFP double positive SKOV3, HTB-20, and CRL-2351 tumor cells were used as
targets in luciferase based killing assays by control (UTD) or CAR-HER2-z (CAR)
macrophages. The effector to target (E:T) ratio was serially titrated from 10:1 down to
1:30 for both effector groups. Bioluminescence was measured using an IVIS Spectrum
(Perkin Elmer, USA). Percent specific lysis was calculated based on luciferase signal
(total flux) relative to tumor alone, using the following formula.
% Specific Lysis = [(Sample signal – Tumor alone signal)/(Background signal – Tumor
alone signal)] x 100
Data is shown as mean +/- SEM, with each condition in triplicate. Negative specific lysis
values indicate more signal than in the tumor alone wells. Statistical significance was
calculated using ANOVA with multiple comparisons; ****p<0.0001; ***p<0.001;
**p<0.01; *p<0.05; ns=non-significant.
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In vitro transcription and RNA electroporation.
In vitro transcription (IVT) was performed using the mMessage mMachine T7 Ultra Kit
(ThermoFisher, AM1345). Briefly, the cDNA for human HER2 was cloned into the pDA
vector downstream of a T7 promoter, linearized with PacI, and IVT was performed per
manufacturer’s instruction. For RNA electroporation, MDA-468 cells were washed twice
in PBS and resuspended in Opti-MEM (ThermoFisher, 31985062). Increasing amounts of
IVT HER2 mRNA were added (from 0 to 20ug) prior to electroporation using the BTX
ECM 830 Square Wave Electroporation System (Harvard Apparatus) using a single pulse
of 300V and 0.7msec. Cells were incubated at 37C overnight and HER2 MFI was
determined via FACS prior to use.
Statistics.
Statistical analysis was performed in Prism 6.0 (GraphPad, Inc). Each figure legend
denotes the statistical test used. Error bars indicate standard error of the mean unless
otherwise indicated. ANOVA multiple comparison p-values were generated using
Tukey’s multiple comparisons test. All t-tests were two-sided. * indicates p<0.05, **
indicates p<0.01, *** indicates p<0.001, and **** indicates p<0.0001.
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Figures
Figure 3.1: Primary human monocyte derived macrophage process overview and
cell purity throughout the process

Figure 3.1:
(A): Overview of the CAR macrophage 7-day manufacturing process and timeline.
(B): Relative abundance of granulocytes, monocytes, T cells, NK cells, and B cells in the
pre-selection or post-selection positive/negative fractions, as determined by FACS
analysis. The post-selection positive fraction was used for macrophage differentiation.
(C): The inter-donor variability in viability and leukocyte purity (macrophages, T cells, B
cells, neutrophils, and NK cells) at the time of harvest from 6 normal donors for both
control (UTD) and CAR macrophages.
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Figure 3.2: RNA electroporation of CAR mRNA is efficient but transient

Figure 3.2:
(A): Electroporation of in vitro transcribed and capped anti-HER2 CAR mRNA of
primary human monocytes. CAR expression and viability are shown from mock
electroporated cells (top row) or CAR electroporated (bottom row) primary human
monocytes, 24 hours post electroporation.
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(B): Electroporation of in vitro transcribed and capped anti-HER2 CAR mRNA of
primary human macrophages. CAR expression and viability are shown from mock
electroporated cells (top row) or CAR electroporated (bottom row) primary human
macrophages, 24 hours post electroporation.
(C): Persistence of expression of the CAR protein on the surface of RNA electroporated
macrophage over the course of seven days, as measured by FACS.

Figure 3.3: Human macrophages express CD46 but not CXADR
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Figure 3.3:
(A): Expression of Ad5-docking protein Coxackie-adenovirus receptor (CXADR) relative
to isotype control antibody (unfilled histogram) on primary human macrophages by
FACS.
(B): Expression of Ad5f35-docking protein CD46 relative to isotype control (unfilled
histogram) on primary human macrophages by FACS.
(C/D): MFI and percent positivity for CXADR and CD46 from 10 donors. Data
represents mean +/- SEM. Statistical significance was determined using t-test;
****p<0.0001.
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Figure 3.4: Ad5f35 is highly efficient in macrophage transduction

Figure 3.4:
(A/B): Primary human macrophages were transduced with GFP encoding viruses at
decreasing dilution factors. Ad5f35, standard 3rd generation VSV-G pseudotyped
lentivirus (Wt LV), or Vpx-packaged lentivirus were compared for transduction
efficiency (A) and expression intensity (B). Viral fraction is calculated as the level of
viral dilution in a serial titration.
(C): Representative image of UTD or Ad5f35-GFP transduced macrophages 48-hours
post transduction.
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Figure 3.5: Representative gating strategy and expression of anti-HER2 CAR on
Ad5f35-transduced macrophages

Figure 3.5:
Representative FACS gating strategy for anti-HER2 CAR and CD86 in UTD (top-row)
and CAR (bottom-row) primary human macrophages.

Figure 3.6: Induction of CD86 by Ad5f35 on macrophages from 10 human donors
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Figure 3.6:
Anti-HER2 CAR construct (top). CAR expression in 10 human donors at an MOI of
1x103 PFU, 48-hours post-transduction, as measured by FACS surface CAR staining
(bottom).

Figure 3.7: Primary human anti-HER2 CAR macrophage phagocytosis and tumor
killing in vitro
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Figure 3.7:
(A): Quantification of phagocytosis by primary human control (UTD) or anti-HER2
CAR-macrophages of MDA-468 (HER2-) or SKOV3 (HER2+). Data is represented as
mean +/- standard error. Statistical significant between CAR-HER2-z and UTD was
calculated using ANOVA with multiple comparisons; ****p<0.0001, ns = nonsignificant.
(B-D): Luciferase+ SKOV3, HTB-20, or CRL-2351 were used as targets in in vitro
cytotoxicity assays with control (UTD) or CAR-HER2-z (CAR) macrophages at different
E:T ratios. Data is shown as mean +/- SEM for triplicate wells. Statistical significance
was calculated using ANOVA with multiple comparisons; ****p<0.0001; ***p<0.001;
**p<0.01; *p<0.05; ns=non-significant.

Figure 3.8: Correlation of CAR expression with phagocytosis and specific lysis
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Figure 3.8:
(A): Human macrophages were transduced with CAR-HER2-z Ad5f35 at MOIs of 0,
100, 500, or 1000 PFU. CAR expression correlated with MOI. Data are represented as
mean +/- SEM. Correlation was determined via linear regression and Pearson correlation.
(B): Human macrophages were transduced with CAR-HER2-z Ad5f35 at MOIs of 0,
100, 500, or 1000 PFU. In vitro phagocytosis of SKOV3 correlated with CAR
expression. Data are represented as mean +/- SEM. Correlation was determined via linear
regression and Pearson correlation.
(C): Human macrophages were transduced with CAR-HER2-z Ad5f35 at MOIs of 0,
100, 500, or 1000 PFU. Luciferase-based specific lysis of SKOV3 at 48-hours correlated
with in vitro phagocytosis of SKOV3 at 4-hours. Data are represented as mean +/- SEM.
Correlation was determined via linear regression and Pearson correlation.
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Figure 3.9: Antigen density regulates anti-HER2 CAR macrophage activity with a
threshold/switch-like pattern

Figure 3.9:
(A-B): Increasing amounts of in vitro transcribed HER2 mRNA were electroporated into
GFP+ MDA-468 (HER2-) target cells to generate titrated antigen expression and was
validated by surface anti-HER2 FACS staining. These cells were used as phagocytic
targets for CAR-HER2 macrophages. Data is shown as mean +/- standard error.
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(C-D): A panel of 10 human cancer cell lines were tested for surface HER2 expression
(isotype and MDA-468 are negative controls). These cell lines were exposed to CARHER2-z macrophages. Percent phagocytosis is shown as a heatmap, with each column
representing a different donor. Cell lines are ordered by HER2-MFI from low-to-high.
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Figure 3.10: Macrophage trafficking and biodistribution in vivo assessed via
imaging

Figure 3.10:
(A): NSGS mice were engrafted with subcutaneous SKOV3 CBG/GFP tumors for 3-4
weeks until large. Mice were injected either intravenously (IV) or intratumorally (IT)
with 5e6 VivoTrack680 labeled human macrophages. Mice were imaged 5 days post
macrophage administration for tumor (luciferase; top row) and macrophages
(VivoTrack680; bottom row). Red represents macrophages.
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(B): Biodistribution of adoptively transferred macrophages via terminal organ harvest and
imaging of VivoTrack680 signal in liver, lung, spleen, and tumor.
(C): Quantification of the relative VivoTrack680 signal in tumor, spleen, lung, and liver
after terminal organ harvest and fluorescent imaging.

Figure 3.11: In vivo anti-tumor activity of anti-HER2 CAR macrophages in a
peritoneal carcinomatosis model

Figure 3.11:
(A): NSGS mice were injected with SKOV3 IP 2-4 hours prior to receiving injections of
either PBS, control (UTD) or CAR-HER2 human macrophages IP as shown.

99

(B-C): Tumor burden, measured by bioluminescence (total flux), and body weight over
100 days.
(D): Kaplan-Meier survival curve over 100 days. Statistical significance was calculated
using Log-Rank Mantel Cox test; ****p<0.0001.

Figure 3.12: In vivo anti-tumor activity of anti-HER2 CAR macrophages in a lung
metastasis model

100

Figure 3.12:
(A): Female NSGS mice were intravenously injected with SKOV3 and treated with IV
macrophages 7 days later as shown.
(B-C): Representative image of tumor burden 31-days post treatment and tumor burden
(total flux) over time.
(D): Kaplan-Meier survival curve. Statistical significance was calculated using Log-Rank
Mantel Cox text; **p<0.01.
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CHAPTER 4: Adenoviral infection polarizes human macrophages toward a proinflammatory phenotype and renders resistance to immunosuppressive cytokines

Abstract
Macrophages constitutively express receptors that allow them to respond to a wide range
of environmental cues, and intracellular signaling mediators and transcription factors that
modify the gene expression profile appropriately in response to each cue. Notably,
macrophages possess a thorough viral recognition program that allows them to respond to
viral pathogen associated molecular patterns with the release of pro-inflammatory factors.
We hypothesized that the Ad5f35 viral vector passively triggers a pro-inflammatory, antitumor phenotype during the CAR engineering process. In this chapter, we show that the
exposure of macrophages to adenoviral vectors leads to the induction of a strong
macrophage interferon signature, the induction of M1 programs, and the enhancement of
the antigen processing and presentation machinery. Furthermore, the response of
adenovirally transduced macrophages to immunosuppressive cytokines was significantly
blunted. Taken together, the results in this chapter demonstrate that Ad5f35 transduced
CAR macrophages are polarized to an irreversible anti-tumor phenotype and demonstrate
augmented T cell priming potential.
Introduction
Macrophages have the capacity to transform their identity, phenotype, activation state,
and function based on tissue and environmental cues (Lavin et al. 2015). Adult bone
marrow derived peripheral blood monocytes traffic into inflamed or damaged tissues
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where they differentiate into macrophages, potentially adopting the local phenotype and
proliferative capacity of tissue resident macrophages (Varol et al. 2015). Within tissues,
macrophages become activated in response to environmental cues. The activation status
of macrophages lies on a spectrum, often defined by its opposing ends: M1 and M2. M1
macrophages are pro-inflammatory - they recruit T cells, upregulate antigen processing
machinery and co-stimulatory ligands, and secrete activating cytokines (IL12, TNF,
IFNy, etc) are therefore thought to exhibit anti-tumor function. M2 macrophages, on the
other hand, are pro-tumoral and immunosuppressive - they upregulate checkpoint
ligands, inhibit T cell function, promote angiogenesis, and secrete inhibitory cytokines
(Mosser & Edwards 2008).
Macrophages are abundant in the tumor microenvironment (TME) of most cancers where
they generally adopt an M2 phenotype and exert pro-tumoral functions such as invasion
and angiogenesis, priming the pre-metastatic niche, facilitating metastasis and
immunosuppression (Noy & Pollard 2014). In the context of an adoptively transferred
macrophage-based cell therapy for cancer, macrophages of the M1 phenotype are likely
to be far more beneficial than M0 or M2 macrophages. In fact, care must be taken to
ensure that the adoptively transferred macrophages are not M2-polarized, as the addition
of M2 immunosuppressive macrophages can potentially worsen the prognosis by
accelerating tumor growth, invasion, and metastasis.
In this chapter, we assess the phenotype and activation state of Ad5f35 transduced CAR
macrophages. Furthermore, we assess the impact of M2 inducing immunosuppressive
cytokines on Ad5f35 transduced CAR macrophages. Macrophages, which are first
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responders of the immune cells, lining the submucosal region of environmental barriers
such as those of the gastrointestinal and respiratory lumens, constitutively expressed
pattern recognition receptors capable of recognizing bacterial, fungal, and viral pathogen
associated molecular patterns. Macrophages express several receptors capable of reacting
to viral patterns – TLR3, TLR7, TLR9, RLR’s, NLR’s, cGAS/STING, and others. We
hypothesized that Ad5f35, a double stranded DNA virus, has the potential to induce an
M1 phenotype by triggering an antiviral response. The induction of an antiviral
macrophage response would enhance the expression of lymphocyte recruiting
chemokines, antigen processing and presentation genes, co-stimulatory ligands, major
histocompatibility complex proteins, and pro-inflammatory cytokines. In this chapter we
explore the impact of Ad5f35 on macrophage phenotype and test the further
responsiveness of these cells to secondary M2 subversion in response to classic
immunosuppressive cytokines IL4 and IL13.

Results
Macrophage phenotype is plastic and can change in response to cytokines, pathogenassociated molecular patterns, metabolic cues, cell-cell interactions, and tissue-specific
signals (Mosser & Edwards 2008). We hypothesized that exposure to Ad5f35, a double
stranded DNA virus, may induce a pro-inflammatory (M1) phenotype. Using non-biased
hierarchical clustering of macrophage transcriptomes from four human donors,
transduced macrophages clustered distinctly from untransduced macrophages,
demonstrating a broad phenotypic shift (Figure 4.1A). Furthermore, when UTD, Ad5f35104

CAR transduced, empty-vector Ad5f35 transduced (Empty), IFNg/LPS stimulated
(classically activated, M1), or IL4 stimulated (alternatively-activated, M2) macrophage
transcriptomes from multiple human donors were subject to non-biased principal
component analysis, adenovirally transduced macrophages clustered toward the
classically-activated and away from the alternatively-activated macrophages, regardless
of CAR expression (Figure 4.1B). Transduction led to the induction of many interferonassociated genes, consistent with a classically-activated M1 phenotype (Figure 4.2; IFI,
interferon induced; ISG, interferon stimulated gene). Unbiased pathway analysis
demonstrated the induction of M1-associated pathways, such as interferon, pattern
recognition receptor, Th1, RLR, JAK1/JAK2, and iNOS signaling (Figure 4.2).
Furthermore, key components of the antigen-presentation machinery such as costimulatory ligand, antigen processing/presentation, and MHC-Class I/II genes were
induced upon transduction (Figure 4.3). We validated the induction of a proinflammatory M1 phenotype by RT-qPCR and flow cytometry, demonstrating an MOIdependent response (Figure 4.4). The induction and repression of these markers was
equivalent between CAR and empty vector Ad5f35, validating that the phenotype is
induced by the vector and not related to expression of CAR in macrophages (Figure 4.5).
Ad5f35 mediated M1-induction was validated on macrophages from 10 human donors
(Figure 4.6).
Given the upregulation of co-stimulatory ligand and antigen processing/presentation
genes, and the established role of macrophages as professional antigen presenting cells
(APCs), we sought to test the capacity for CAR macrophages to co-stimulate and present
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antigens to T-cells. CD8+ T-cells stimulated with phytohemagglutinin (PHA) in vitro, a
non-specific mitogen, proliferated significantly more in the presence of transduced versus
untransduced macrophages (Figure 4.7A). To test the capacity for Ad5f35-transduced
macrophages to process and present antigen, we transduced macrophages with the tumorassociated antigen NY-ESO1 and the HLA-A2*01 molecule. Macrophages were then
transduced with Ad5f35, or not (UTD), and co-cultured with transgenic anti-NY-ESO-1
(1G4) TCR+ autologous T-cells. Ad5f35-transduced NY-ESO1-expressing macrophages
induced significantly more proliferation of 1G4+ CD8+ T-cells than NY-ESO1expressing control macrophages or Ad5f35 transduced macrophages lacking NY-ESO1
(Figure 4.7B). In order to test the potential of CAR macrophages to stimulate T-cells in
vivo, NSGS mice were engrafted with metastatic SKOV3 and treated with CAR
macrophages, CAR macrophages plus donor-derived polyclonal T-cells (CAR+T), Tcells alone, or left untreated. Mice treated with CAR macrophages plus donor-derived Tcells had deeper anti-tumor responses (Figure 4.8A) and generated more xenogeneic
graft-versus host disease (data not shown) than the control conditions, suggesting that
Ad5f35-transduced macrophages stimulated autologous T-cells in vivo (Figure 4.8B). In
addition, given the enhanced physiological relevance of this semi-immune reconstituted
mouse model, we measured peripheral blood chemistries to track any over toxicity, and
saw no impact on red blood cell count, hemoglobin, hematocrit, platelet count, alanine
aminotransferase, aspartate aminotransferase, and creatinine (Figure 4.9).
To address the potential concern that adoptively transferred macrophages may respond to
M2-inducing cytokines, we sought to test phenotype plasticity by challenging control or
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Ad5f35-transduced human macrophages with two canonical M2-inducing cytokines, IL4
or IL13. Upon stimulation with IL4, IL13, or SKOV3-conditioned media, only UTD
macrophages upregulated the canonical M2 marker CD206 (Figure 4.10A). Furthermore,
upon stimulation with IL4 only UTD macrophages increased their basal oxygen
consumption rate, an expected characteristic of IL4-induced M2 macrophages (Figure
4.10B) (Kelly & O’Neill 2015). Transcriptome analysis revealed significantly fewer
genes were induced by IL4 or IL13 in CAR versus UTD macrophages, including the
CD206 encoding M2-associated gene MRC1 (Figure 4.11). Collectively, these results
demonstrate that Ad5f35 induces a potent pro-inflammatory M1 macrophage phenotype
during the transduction process, promotes the ability of macrophages to stimulate
adaptive immunity, and reduces the responsiveness of macrophages to M2-inducing
cytokines.
Discussion
In Chapter 4, we explore the phenotype of Ad5f35-transduced primary human CAR
macrophages. Macrophages are highly plastic cells with a wide spectrum of activation
states. We hypothesized that the transduction of macrophages with an adenoviral vector,
regardless of the payload transgene (in this case CAR), may induce an M1 phenotype by
triggering viral recognition receptors and leading to an interferon response. We show that
transduction with Ad5f35 leads to a broad gene expression change as determined by
RNA sequencing. Upon analyzing the transcriptome of transduced macrophages and
comparing them to classically or alternatively activating macrophages, we show that
Ad5f35 transduced macrophages cluster in the direction of classically activated cells.
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Further validating the M1 phenotype of Car macrophages, we show that Ad5f35
transduction leads to the upregulation of co-stimulatory ligands, activating cytokines,
numerous chemokines, and a myriad of genes of the antigen processing and presentation
machinery. Nonbiased analysis of the transcriptome shows that there is a strong
interferon signature in Ad5f35 transduced macrophages. Given that macrophages are
antigen presenting cells, we hypothesized that activated M1 Ad5f35 transduced CAR
macrophages may have augmented T cell priming activity. In several T cell activation
assays, Ad5f35 transduced macrophages led to enhanced T cell proliferation, suggesting
that the viral priming and phenotypic reprogramming augments their APC activity and
enhances the likelihood of CAR macrophages leading to epitope spreading in an
immunotherapeutic setting.
Interestingly, and perhaps surprisingly, the response to two classic M2 inducing
immunosuppressive cytokines, IL4 and IL13, was strongly blunted or even absent in
Ad5f35 transduced macrophages. We confirmed these findings on a transcriptomic,
metabolic, and M2 surface phenotypic marker level. The specific mechanism by which
Ad5f35 transduced macrophages were resistant to IL4 and IL13 remains to be
determined, but likely involves epigenetic reprogramming at a chromatin level that
renders the response to these cytokines ineffective in inducing M2 gene expression
changes.
While the data show that the CAR macrophages generated in this thesis are M1 polarized
and resistant to IL4 and IL13, the importance of the phenotype in more physiologically
relevant animal models with intact immune systems and tumor microenvironments
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remains to be determined. Furthermore, while we show in vitro resistance to several
immunosuppressive cytokines, the tumor microenvironment has a myriad of potentially
suppressive factors that we are unable to model in vivo. The persistence of the M1
phenotype of CAR macrophages within the tumor will be the subject of correlative
studies in a future clinical trial.

Materials and Methods
Primary human macrophages and T-cells.
Normal donor apheresis was either performed at the hematology unit at the Hospital of
the University of Pennsylvania under an IRB approved protocol through the Human
Immunology Core of the University of Pennsylvania or were acquired and shipped fresh
from HemaCare (HemaCare Corporation, CA, USA). Apheresis derived leukopacs were
subject to elutriation using an Elutra Cell Separation System (Terumo BCT) to reduce
erythrocytes, platelets, lymphocytes, and granulocytes. Monocyte enriched fractions were
pooled and subjected to MACS CD14 positive selection (Miltenyi) per manufacturer’s
instruction. The pre-selection and post-selection (positive and negative fraction) purity
was tested using flow cytometry. Selected CD14 monocytes were seeded in Cell
Differentiation Bags (Miltenyi) in RPMI with 10% FBS, penicillin, streptomycin, 1x
glutamax, 1x HEPES, and 10ng/mL recombinant human GM-CSF (Peprotech, 300-03)
for 7 days. Differentiation was monitored by light microscopy. Adenovirus was added on
day 5 at an MOI of 1x103 based on plaque-forming unit (PFU) titer. Differentiated
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macrophages were harvested at day 7 and tested for CAR expression, differentiation, and
macrophage purity by FACS. For smaller scale experiments macrophages were plated
directly in tissue-culture treated well-plates or flasks and transduced at an MOI of 1000
PFU directly in well plates or flasks. CD3 selected T-cells were provided by the
University of Pennsylvania Human Immunology Core and were expanded/transduced as
previously described.
Macrophage polarization.
For M1 or classically-activated macrophage polarization, human monocyte derived
macrophages were exposed to 20ng/mL recombinant interferon-g (Peprotech, 300-02)
and 100ng/mL lipopolysaccharide (LPS-EK, Invivogen, tlrl-eklps) in RPMI with 10%
FBS for 24 hours. For M2 or alternatively activated macrophage polarization, human
monocyte derived macrophages were exposed to 20ng/mL recombinant human IL4
(Peprotech, 200-04) or IL13 (Peprotech, 200-13). In some experiments, 48-hour
conditioned media from SKOV3 was used (50% diluted in RPMI with 10% FBS) to
polarize macrophages toward M2 for 24 hours. In experiments where control or CAR
macrophages were challenged with M2 inducing cytokines, cells were treated with
cytokine for 24 hours, 48 hours post-viral transduction.

RNA-sequencing of human macrophages.
RNA was isolated from human macrophages from matched donors, treated as described
in each figure and polarized/challenged as above using Ambion RiboPure RNA
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purification kit (Thermo Fisher Scientific, AM1924). RNA-seq libraries were generated
using TruSeq RNA Library Prep Kit (Illumina, RS-122-2001/2) and validated via BioA
by the University of Pennsylvania Next Generation Sequencing Core facility prior to
sequencing. The libraries were sequenced on 75bp single-end reads using a NextSeq
sequencer (Illumina). Low quality reads were trimmed using Trimmomatic (v0.36) and
mapped to human genome (hg38) using STAR (v2.6.0c) with default parameters. Gene
count was calculated using featureCounts (v1.6.1)(Liao et al. 2014). Non-expressed genes
with read count < 1 in all samples were removed prior to differential expression analysis.
DESeq2 with log fold change of 1 and adjusted P-value of 0.05 was used to identify
differentially expressed genes.

For genome browser tracks, bam files were first converted into bed files using bedtools
(v2.27.1). Normalized bedgraph tracks were generated using makeUCSCfile with
10,000,000 normalization factor (Homer v2) and converted into bigwig format for
integrative genomics viewer (IGV; Broad Institute) usage. Reads were mapped to the
human genome (hg38) using RUM prior to using DegSeq and EdgeR for differential
analysis. Group auto-scale was applied to all conditions for y-axis equalization in IGV.
Ingenuity Pathway Analysis (Qiagen Bioinformatics) was used to map differentially
expressed genes to canonical pathways.

Real-time PCR.
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RNA was isolated using Ambion RiboPure RNA purification kit (Thermo Fisher
Scientific, AM1924) and reverse transcribed using iScript RT Supermix for RT-qPCR
(Bio-Rad, 1708841). For q-PCR, template cDNA, primers, Taqman Gene Expression
primer/probe, and Taqman Gene Expression Master Mix (Applied Biosystems, 4369016)
were used per manufacturer’s instructions. The following human primer/probes from
Applied Biosystems were used: TNF (Hs00174128_m1), IL12A (Hs01073447_m1),
GAPDH (Hs02786624_G1), TAP1 (Hs00388675_m1), CD206 (Hs00267207_m1), CD80
(Hs01045161_m1), and IFNb (Hs01077958_s1).

T-cell stimulation assays.
Phytohemagglutinin T cell proliferation assay :
Human T-cells were labeled with CellTrace CFSE Cell Proliferation Kit (ThermoFisher,
C34554) per manufacturer’s protocol. CFSE labeled T-cells were cultured alone or at a
1:1 E:T ratio for 5 days with control UTD or transduced CAR-HER2-z autologous
macrophages in the presence or absence of 0.5% phytohemagglutinin (PHA-L, SigmaAldrich, 11249738001). Proliferation of CD8 T-cells was determined by FACS by
measuring the % loss of CFSE (CFSE dilution).
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NY-ESO-1 antigen processing and presentation assay:
Primary human macrophages were transduced with HLA-A201-P2A-NY-ESO1 Vpx
lentivirus or not (Ag and No Ag, respectively). 1G4 NY-ESO-1 TCR T-cells were
generated as previously described and stained with CellTrace Violet (CTV) Cell
Proliferation Kit (ThermoFisher, C34557) per manufacturer’s instruction(Rapoport et al.
2015). 48 hours post lentiviral transduction, macrophages were transduced with Ad5f35CAR-HER2-z for polarization, or not, for an additional 48 hours prior to the addition of
CTV labeled 1G4 anti-NY-ESO1 TCR autologous T-cells for 5 days. Proliferation of
anti-NYESO1 TCR+ CD8+ T-cells was determined by FACS by measuring dilution of
CTV.

Mitochondrial respiratory analysis in human macrophages.
Mitochondrial function was assessed using an extracellular flux analyzer
(Agilent/Seahorse Bioscience). Primary human control or CAR macrophages (48-hours
post-transduction), with or without 24-hour exposure to 20ng/mL recombinant human IL4 (Peprotech, 200-04) were seeded at 1x105 cells/well onto XF96 cell culture
microplates. To assay mitochondrial function, the medium was replaced with XF assay
base medium supplemented with 5.5mM glucose, 2mM L-glutamine and 1mM sodium
pyruvate. Prior to use, XF96 assay cartridges were calibrated in accordance with the
manufacturer’s instructions. During instrument calibration (60min) the cells were
switched to a CO2-free, 37 °C, incubator. Cellular oxygen consumption rates (OCR) and
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extracellular acidification (ECAR) levels were measured under basal conditions and
following treatment with 1.5 μM oligomycin, 1.5 μM fluoro-carbonyl cyanide
phenylhydrazone (FCCP) and 40nM rotenone, with 1μM antimycin A.
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Figures
Figure 4.1: Ad5f35 transduced macrophages undergo a broad gene expression
change and cluster toward the M1 phenotype

Figure 4.1:
(A): Hierarchical clustering of differentially expressed genes from UTD or Ad5f35-CARHER2-z transduced human macrophages from 4 matched donors, 48 hours post
transduction. The heatmap shows log2 fold-change in gene expression relative to UTD.
(B): Transcriptome-derived principal component analysis clustering from UTD, Ad5f35empty vector transduced, Ad5f35-CAR-HER2-z transduced, classically-activated M1 or
alternatively-activated M2 human macrophages. Replicates represent distinct human
donors.
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Figure 4.2: Ad5f35 transduction of macrophages leads to M1 and interferon
associated pathway induction

Figure 4.2:
(A): Table of Ad5f35 induced canonical pathways in human macrophages.
(B): Volcano-plot of UTD vs. Ad5f35-CAR-HER2-z macrophage differentially
expressed genes. Purple indicates p-adj <0.05 and log2 fold change >1 or <-1. Red
triangles indicate upregulated interferon-associated genes.
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Figure 4.3: Ad5f35 transduction induces upregulation of co-stimulatory ligands,
antigen presentation genes, and MHC Class I/II molecules

Figure 4.3:
(A-C): Gene expression heatmaps of represented co-stimulatory ligands, antigen
processing/presentation, and MHC class I/II genes from 3 normal donors as determined
by RNA sequencing of control UTD or Ad5f35 transduced CAR macrophages.
Expression is normalized to UTD for each gene.
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Figure 4.4: The M1 induction by Ad5f35 is MOI-dependent and CAR-independent

Figure 4.4:
(A): Surface expression of select human M1 markers (CD80 and CD86) and M2 marker
CD163 in response to transduction with increasing MOIs of Ad5f35-CAR by FACS.
Data is represented as mean +/- SEM of the mean fluorescent intensity (MFI) of each
marker for duplicate wells.
(B): Surface expression of human M1 markers (CD80 and CD86) and M2 marker CD163
after transduction with equivalent MOIs of control empty-vector Ad5f35 or Ad5f35CAR. Data is represented as mean +/- SEM of the MFI of each marker for duplicate
wells.
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Figure 4.5: Reverse transcription real time PCR confirmation of RNA sequencing
results

Figure 4.5:
Confirmation of select M1 genes by RTqPCR from human macrophages transduced with
increasing MOIs of Ad5f35-CAR. GAPDH was used as a housekeeping control gene.
Data is represented as mean +/- SEM. Statistical significance was calculated using
ANOVA with multiple comparisons; ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05;
ns=non-significant.
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Figure 4.6: Induction of the M1 marker CD86 on macrophages from 10 human
donors

Figure 4.6:
Surface expression of M1 marker CD86 on control UTD or Ad5f35-CAR transduced
macrophages from 10 human matched-donors.
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Figure 4.7: Ad5f35-transduced CAR macrophages demonstrate augmented T cell
stimulation in vitro

Figure 4.7:
(A): CFSE labeled T cells were cultured alone or at a 1:1 E:T ratio for 5 days with UTD
or autologous CAR macrophages in the presence or absence of PHA. Proliferation of
CD8 T cells is shown as percent of CFSE(-)CD8(+) T cells, mean +/- SEM. (***p<0.001;
ns=non-significant.)
(B): Control or NY-ESO-1 expressing macrophages (No Ag and Ag, respectively), with
or without Ad5f35-CAR were co-cultured with CTV-labeled anti-NY-ESO-1 T cells.
Proliferation of anti-NY-ESO-1 TCR+ CD8+ T cells is shown as mean +/- SEM.
Statistical significance was determined using ANOVA with multiple comparisons.
****p<0.0001.
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Figure 4.8: In vivo anti-tumor response in a semi-immune reconstituted model

Figure 4.8:
(A): NSGS mice were IV injected with SKOV3 as shown in Figure 2m. 7 days later mice
were treated with either IV PBS, CAR macrophages (8x106) +/- autologous T cells
(3x106), or T cells alone. Tumor burden over time is shown for each mouse.
(B): Peripheral blood CD8+ human T-cell counts over the course of 8 weeks post
treatment in mice that received T cells are T cells and CAR macrophages, as quantified
by FACS per 25uL blood.
(C): Peripheral blood CD4+ human T-cell counts over the course of 8 weeks post
treatment in mice that received T cells are T cells and CAR macrophages, as quantified
by FACS per 25uL blood.
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Figure 4.9: CAR macrophages have a promising in vivo blood chemistry safety
profile

Figure 4.9:
Peripheral blood derived toxicity measures including red blood cell count (RBC),
hemoglobin level (HGB), platelet count, alanine aminotransferase (ALT), aspartate
aminotransferase (AST), and creatinine from SKOV3 tumor bearing NSGS mice treated
with nothing (untreated), empty Ad5f35 vector transduced, or anti-HER2 CAR
macrophages intravenously.
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Figure 4.10: Ad5f35-transduced CAR macrophages are resistant to
immunosuppressive cytokines

Figure 4.10:
(A): Upregulation of CD206 in response to M2-challenge in UTD or CAR macrophages
(representative histograms; top panel, %CD206(+) in response to IL-4; bottom panel).
Data is shown as mean +/- SEM from triplicate conditions. Statistical significance was
calculated with t-test (****p<0.0001; CAR vs. UTD).
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(B): The change in oxygen consumption rate (OCR) upon treatment with IL-4 in UTD or
CAR macrophages (representative OCR diagrams, top panel; mean basal OCR; bottom
panel). Data is shown as mean +/- SEM from triplicate conditions. Statistical significance
was calculated with t-test (***p<0.001; CAR vs. UTD).
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Figure 4.11: CAR macrophages have a blunted response to IL4 and IL13 on a
transcriptome wide level

Figure 4.11:
(A): Volcano plot of IL4 response genes in UTD or CAR macrophages from RNA
sequencing. Genes on the left represent IL4-downregulated genes, while genes on the
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right represent IL4-upregulated genes. Red indicates p-adj <0.05 and log2 fold change >1
or <-1.
(B): Venn diagram shows the number of IL4 M2-cytokine induced genes in UTD, CAR,
or both macrophage types.
(C): Mapping of the RNA-sequencing results to the known M2 gene MRC1 (CD206)
demonstrate a lack of response to IL4 in the CAR but not UTD condition.
(D): Volcano plot of IL13 response genes in UTD or CAR macrophages from RNA
sequencing. Genes on the left represent IL13-downregulated genes, while genes on the
right represent IL13-upregulated genes. Red indicates p-adj <0.05 and log2 fold change
>1 or <-1.
(B): Venn diagram shows the number of IL13 M2-cytokine induced genes in UTD, CAR,
or both macrophage types.
(C): Mapping of the RNA-sequencing results to the known M2 gene MRC1 (CD206)
demonstrate a lack of response to IL13 in the CAR but not UTD condition.
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Chapter 5: Conclusion, discussion and future directions
Current macrophage minded approaches to cancer immunotherapy aim to deplete the
tumor-promoting mechanisms of TAMs or to engage their phagocytic activity. In this
thesis, we hypothesized that genetically engineering macrophages with CAR may rewire
phagocytic activity and lead to targeted anti-tumor activity. In this thesis, we introduce
the concept of CAR macrophages, demonstrate for the first time the activity of CAR on
human macrophages, realize the concept toward an immediately translatable primary
human cell format, and provide data and rationale for the use of CAR macrophages as a
platform for the cellular immunotherapy of human cancer.

In chapter 2, we show that the introduction of CD3-zeta and Fc-gamma based CARs into
THP-1 macrophages allow for the phagocytic activity of cognate-antigen bearing human
tumor cells. Importantly, the phagocytic activity of Car macrophages is demonstrated in
the absence of any additional opsonizing agents such as monoclonal antibodies or
complement, and in the absence of blockade of the inhibitory CD47/SIRPa axis. To our
knowledge, this is the first study demonstrating that the addition of a single gene can
redirect the phagocytic activity of tumor cells by human macrophages. The foundational
proof-of-concept data using the THP-1 model was performed using anti-CD19 CARs, a
well-studied model antigen in our lab. We chose this antigen as a model of CAR
mediated activity, rather than as a potential clinical target, as anti-CD19 CAR-T cells are
inducing deep remissions in several CD19 positive malignancies.
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The functionality of CD3-zeta, a molecule which naturally is not expressed in
macrophages, as the intracellular signaling domain of the macrophage CAR is perhaps
surprising. CD3-zeta is naturally a component of the T-cell receptor complex and is a Tcell specific gene. In this study, we did not assess the specific signaling mechanisms or
second messenger systems by which CD3-zeta activates phagocytosis. However, given
the dependence on Syk, actin polymerization, and non-muscle myosin IIA activity, our
data suggests that CD3-zeta is achieving phagocytosis via activation of the Fc-gamma
program. In support of this concept, CD3-zeta and FcERI are highly similar in both
sequence and structure, with CD3-zeta being the evolutionary result of FcERI duplication
and mutation.

Upon deletion of the intracellular domain of anti-CD19 CARs in the THP-1 macrophage
system, phagocytosis of CD19 positive cells was lost. This result suggests that there is a
requirement for an ITAM-bearing intracellular signaling motif. In addition, we mutated
the tyrosine residues of the CD3-zeta ITAMs to phenylalanines, which cannot be
phosphorylated, and saw the loss of phagocytic activity, suggesting that CAR ITAM
phosphorylation is required for activity in macrophages, just as in CAR T and CAR NK
cells. Whether the specific choice of ITAM-bearing intracellular domain holds potential
to impact the phagocytic activity remains to be determined. Interestingly, though
phagocytosis was abrogated in the CD3-zeta null (delta-zeta) CAR, killing of target
bearing tumor cells was strongly reduced but not completely lost. This result suggests
that there may be killing mechanisms other than phagocytosis, and that the binding of an
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scFv on the surface of a macrophage to an antigen on the surface of a tumor cell may lead
to a low level of anti-tumor activity. The exact mechanism of killing by delta-zeta CARs,
and the secondary non-phagocytic mechanisms by which CAR macrophages exert antitumor activity, are the subject of future research. In this thesis, we compared CD3-zeta
and Fc-gamma based CARs against CD19 in terms of both phagocytosis, Syk
dependence, and in vitro tumor killing, and were unable to detect any statistically
significant differences. It is worth noting, however, that while the THP-1 model is
representative of human macrophage phagocytosis, it is possible that the intracellular
domains of CARs will behave differently in primary human macrophages. Future work
will closely assess and compare the functionality of various intracellular domains in
primary human macrophages.

The design of the CAR structures used in this thesis are based on CARs that have been
optimized for T cells. We used a CD8a leader sequence, an scFv-based antigen
recognition domain, a CD8a hinge, a CD8a transmembrane domain, and a CD3-zeta
based intracellular domain. The biophysical interaction of macrophages with targets is
distinct from that of T cells with targets, and thus it is likely that, while functional, the Tcell based CAR may not be optimal for macrophage effector activity. Future work will
aim to optimize the extracellular and intracellular domains of macrophage CARs. The
impact of CAR length, dimerization, tonic signaling, stimulation, and co-stimulation on
phagocytosis and other macrophage effector activity remains to be determined. Notably,
in this thesis we exclusively utilized “first-generation” CARs, lacking a secondary co130

stimulatory intracellular domain. The addition of a rationally-designed macrophage costimulatory, pro-phagocytic, or activating co-stimulatory domain is the subject of future
research. Of particular interest are co-stimulatory domains derived from phagocytosis
pathways distinct from and synergistic to the Fc receptor family pathways. Accordingly,
a promising group of receptors that may augment CD3-zeta CAR based phagocytosis are
the complement receptors. Complement has been shown to augment phagocytosis of
antibody opsonized target cells independently of Fc receptors. The complement pathway
is a complex cascade comprised of a series of zymogens that directly or indirectly (via
antibody-antigen complexes) opsonize the surface of targets and leads to the activation of
pro-inflammatory mediators, chemokines, and phagocytic signals, and is thus is a key
component of innate immunity. Complement derived phagocytic signals, such as C3b,
iC3b, and C4b can activate phagocytic complement receptors such as CR1 (CD35), CR3
(CD11b/CD18), and/or CR4 (CD11c/CD18) on monocytes and macrophages (Bakema &
van Egmond 2014; Stasiłojć et al. 2016). The signaling pathways downstream of CR1,
CR3, and CR4 activation are distinct from Fc receptor mediated pathways, and thus the
intracellular domains of these receptors may potentially be effective co-stimulatory
domains in macrophage CARs. Overall, the incorporation of co-stimulatory domains is
the subject of future research.

In Chapter 3, we establish the CAR macrophage concept in primary human macrophages
and provide proof-of-concept in vitro and in vivo efficacy data against a clinically
relevant solid tumor associated antigen – HER2. Genetic manipulation of human
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monocytes and macrophages has been a long-standing challenge in the field. Retroviral
transduction with either gamma-retrovirus or HIV-1 based lentivirus requires high
multiplicities of infection, which for integrating viruses, pose risks for insertional
mutagenesis. In addition, given that human monocytes and macrophages do not expand
ex vivo, the use of high MOI retroviral vectors to transduce ~3x109 cells per donor would
not be technically feasible. Even at high multiplicities of infection, retroviral vectors
demonstrate low levels of macrophage transduction. The addition of Vpx, a SAMHD1
degrading HIV-2 protein, into HIV-1 based LV vectors enhances the transduction
efficiency but still required high MOIs to achieve high transduction rates. Adenoassociated virus vectors of various serotypes failed to transduce human macrophages ex
vivo. Chemical approaches such as lipofection and others generally show inefficient
macrophage transfection with high rates of cell toxicity. We show that the electroporation
of in vitro transcribed CAR mRNA is highly efficient but leads to toxicity and is transient
in expression, lasting less than 5 days on the cell surface.

Ad5, the most commonly used adenoviral serotype in gene therapy, binds to the
Coxackie-adeno receptor on the surface of target cells in order to facilitate entry. Human
macrophages do not express the Coxackie-adeno receptor. Ad35, however, binds to the
CD46 protein for entry, and human monocytes and macrophages ubiquitously express
this protein on their surface. We thus hypothesized that Ad5f35, a chimeric adenoviral
vector with the fiber of Ad35 cloned in place of the Ad5 on an Ad5 vector plasmid, may
lead to high levels of primary human macrophage transduction. We show that Ad5f35
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leads to the mean CAR transduction rate of ~70% of macrophages at an MOI of 1000
PFU per cell.

The use of Ad5f35 to deliver CAR enabled our studies of the activity of primary human
monocyte derived anti-HER2 CAR macrophages. We demonstrate that like with THP1’s, primary human macrophages can trigger phagocytosis and tumor clearance with the
introduction of CD3-zeta based CARs in the absence of additional opsonization. The
activity of primary human macrophages directly correlated with CAR density and HER2
negative cells were not phagocytosed by anti-HER2 CAR macrophages. Furthermore, we
correlated CAR activity with antigen density, and HER2 positive but dim cells
demonstrated resistance to CAR mediated phagocytosis.

Using NSGS mouse models, we grew SKOV3 xenografts and treated mice either
intravenously or intraperitoneally with a single injection of anti-HER2 CAR
macrophages. In mice that received CAR, but not control UTD, macrophages the overall
survival was significantly improved, and tumor burden regressed. In these models, mice
were treated with a single dose of CAR macrophages. A key question to the in vivo
activity of CAR macrophages is their overall and function persistence. Based on the
kinetics of the anti-tumor response, our data suggest that CAR macrophages persist on
the order of weeks but not months. This suggests that there may potentially be a need for
multiple doses of CAR macrophages to sustain response, unless epitope spreading via
antigen presentation leads to the adaptive rejection of tumor. The appropriate dosing
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schedule of CAR macrophages will be empirically optimized in future studies and will
likely vary by target and model. Whether the persistence and activity of human
macrophages in NSGS mice is predictive of activity in humans, with intact immune
systems, remains to be determined in clinical trials. There are pros and cons to the NSGS
immunocompetent xenograft model – the activity seen is directly mediated by the
adoptively transferred CAR macrophages, as there is no adaptive immunity for the cells
to present antigen to. This suggests that in the setting of immunocompetency CAR
macrophages may lead to deeper and more prolonged anti-tumor responses. On the other
hand, by definition the tumor microenvironment in immunocompromised animals is
missing or deficient, and as such lacks several of the barriers which reduce responses to
therapy. In order to test synergistic action between CAR macrophages and the adaptive
immune system, we co-injected NSGS mice with CAR macrophages and donor-derived
non-engineered T cells and showed an increased tumor regression, suggesting that there
is cross-talk between CAR macrophages and T cells occurring. Future work will assess
the role of CAR macrophages in syngeneic or humanized mouse models.

A potential concern of the use of autologous primary human monocyte derived
macrophages is a limited supply of cells. On average, an apheresis yields approximately
3x109 peripheral blood monocytes. Given the lack of expansion of monocytes ex vivo,
the maximum CAR macrophage yield with a single apheresis round is indeed 3x109.
Whether or not 3x109 is an effective dose remains to be determined in clinical trials, as
pharmacokinetic modeling of cell therapies in mice cannot be allometrically scaled. In
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addition, if patients require multiple infusions of 3x109 cells, there is a limit in the
feasibility and clinical appropriates of repeat apheresis. Future work will examine the
induction of expansion of human monocytes and macrophages ex vivo. Studies have
shown the deletion of c-Maf and Maf-B in murine macrophages lead to non-neoplastic ex
vivo expansion (Aziz et al. 2009). Other studies have shown that the deletion of Hoxb8 in
murine macrophages couples with the expression of a constitutively active GM-CSF
receptor leads to proliferation (Lee et al. 2017). The large-scale expansion of human
monocytes and macrophages ex vivo remains enigmatic. Alternatively, studies have
shown that the administration of mobilizing agents, such as GM-CSF, G-CSF, or
plerixafor, studied for their mobilization of CD34 positive hematopoietic stem cells,
increase the number of circulating monocytes by several fold. The pre-treatment of
patients prior to monocyte collection serves as an approach to increase the maximal dose
per manufacturing cycle.

Furthermore, given that macrophages do not express T cell receptors and are not capable
of inducing graft versus host immunity, the use of allogeneic or universal donor CAR
macrophages holds promise. The use of universal donor TCR deleted CD19 CAR-T cells,
still expressing variable MHC which rendered the CAR-T cells susceptible to rejection,
were effective in the treatment of leukemia with pre-conditioning therapy (Qasim et al.
2017). The utility of allogeneic macrophages is conceptually safe in that graft versus host
disease would be highly unlikely. The rejection of the grafted macrophages may be an
issue, but with pre-conditioning the macrophages may persist long enough to cause tumor
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regression. In addition, further genetic modifications of CAR macrophages to decrease
the potential for allogeneic rejection using gene editing techniques are possible and are
the subject of future investigation.
Past clinical trials with autologous monocyte derived macrophages and the in vivo
murine studies presented in this thesis demonstrate trafficking of macrophages to sites of
tumor. Despite these data, the thorough understanding of macrophage biodistribution
throughout the system will have important safety and efficacy implications. Macrophages
are likely to distribute to all major organs, subject to blood flow and route of
administration. We anticipate that the lungs will be a major initial location of macrophage
accumulation, with the liver being the subsequent and perhaps final location in which
systemically infused macrophages will accumulate. Our data in NSGS mice does not
demonstrate any difference in the biodistribution or trafficking of CAR macrophages as
compared to untransduced macrophages, but these mouse models do not accurately
reflect the human condition as there are several issues of absent cross-reactivity
(chemokines, stromal interactions, target antigen, and normal tissue antigen expression).
In terms of efficacy, it is likely that efficacy will correlate with the accumulation of CAR
macrophages at sites of disease, and macrophage loss to normal tissues will reduce the
effective dose at the appropriate site. It is possible that patients with lung and liver
metastases may be the patients to potentially benefit most from this therapy, as
macrophages naturally distribute to lungs and liver. Whether adoptively transferred
macrophages can cross the blood-brain-barrier and traffic to the central nervous system
remains to be determined.
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The persistence of CAR-T cells correlates with depth and persistence of response (van
der Stegen et al. 2015; Maus & June 2016; Song et al. 2011; Priceman, Gerdts, et al.
2018). The persistence of macrophages is highly variable, depends on source, and is the
subject of current research in the field. Bone marrow monocyte-derived inflammatory
macrophages are generally short or intermediate in their lifespan (days to months), while
embryonically derived tissue resident macrophages (microglial cells, Kupffer cells,
alveolar macrophages, etc) can persist for many years and potentially a lifetime (Parihar
et al. 2010). The persistence of tissue resident macrophages is due to both a prolonged
lifespan and a stem-like ability to proliferate (Hashimoto et al. 2013). The persistence and
fate of tumor associated macrophages has not been fully elucidated. Based on the kinetics
of our in vivo experiments in mice, it is likely that the persistence of Ad5f35 transduced
CAR macrophages is approximately several weeks to several months. Whether the native
tissue and cytokine profile in human patients will create a more supportive niche for
human macrophage persistence remains to be determined. If the persistence of
macrophages is indeed limited in human patients, the safety profile of CAR macrophage
treatment will be improved but the efficacy may be reduced - patients may potentially
need multiple serial infusions.

In order to further enhance the potency and activity of human CAR macrophages, several
rationally designed combination therapies hold promise. In this thesis, we assessed the
synergy between blockade of the CD47/SIRPa axis in the THP-1 CD19 CAR model. In
future work, we will assess the synergy between primary human CAR macrophages
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against solid tumor targets in order to understand the potential for the combination with
antibody inhibitors of either the ligand or the receptor of the anti-phagocytic axis.
Furthermore, studies have shown the PDL1/PD1 interaction is anti-phagocytic, and
logically, the blockade of this axis may potentially augment CAR phagocytosis (Gordon
et al. 2017). In addition, the combination with T cell check point inhibitors may act to
enhance the antigen presentation capacity of CAR macrophages.

Currently, CAR-T cell regimens require chemotherapeutic lymphodepletion prior to the
infusion of autologous T cells. Lymphodepletion is thought to reduce regulatory T cells
and increase the availability of cytokines such as IL-7 and IL-15 that promote T cell
engraftment and proliferation. The precise mechanisms by which lymphodepletion acts to
benefit CAR-T cell function is yet to be determined. This raises the question – will
conditioning be required for macrophage adoptive transfer? Furthermore, are adoptively
transferred macrophages more likely to traffic to tumors that are macrophage rich,
suggesting they are actively producing myeloid chemo-attractants, or tumors that are
macrophage poor, which have a greater niche for macrophages to fill? These experiments
require immunocompetent models and will be the subject of future investigation.

Given that macrophages are a highly plastic cell type with the potential to adopt a broad
spectrum of activation states, it is paramount that macrophages adoptively transferred in
the context of cancer maintain an anti-tumor or M1 phenotype. In Chapter 4 we
demonstrate that adenovirally infected macrophages adopt an irreversible M1 phenotype
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and demonstrate resistance to M2 subversion. We show that upon transduction with the
adenoviral vector Ad5f35, macrophages undergo a broad gene expression change
associated with a strong interferon signature. Transduced macrophages upregulated
cytokines, co-stimulatory ligands, antigen processing and presentation genes, and MHC
molecules – suggesting that these engineered cells have passively acquired an antitumoral phenotype. We tested the antigen presentation and T cell priming activity of
transduced macrophages and show that relative to control macrophages, activated Ad5f35
transduced CAR macrophages led to enhanced T cell proliferation in vitro and in vivo.
Macrophages are sentinel immune cells of the innate immune system and are professional
antigen presenting cells. A major rationale in the choice of macrophages for CAR-based
adoptive cellular immunotherapy is that after CAR-mediated phagocytosis, macrophages
may process and present antigen and lead to epitope spreading. In Chapter 4, we show
that Ad5f35-polarized M1 macrophages upregulate a myriad of genes that augment
antigen processing, antigen presentation, and T cell stimulation. We show that
macrophages up-regulate co-stimulatory ligands and that Ad5f35 transduced
macrophages stimulate stronger T cell responses to artificial endogenous antigens than
control untransduced T cells. A major next step will be to demonstrate MHC-II
presentation and MHC-I cross-presentation of phagocytosed tumor-derived antigen.
Cross-presentation assays are the subject of future research. Experimentally, this question
can be approached in two ways. In one approach, immunopeptidomics can be used to
measure tumor derived peptides eluted from CAR macrophage MHC-I or MHC-II. In
another approach, target tumor cells could be engineered to over-express the intracellular
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antigen NY-ESO-1 and CRISPR edited to induce MHC-I knockout, such that target cells
cannot present endogenous antigens. Wild type or NY-ESO-1+/MHC-I- target cells can
be used as phagocytic targets for control or CAR macrophages. Following an incubation
period for phagocytosis and antigen presentation, the activation of NY-ESO-1 specific
transgenic TCR T cells can be used to detect cross-presented NY-ESO-1 antigen on the
CAR macrophage surface. These experiments are the subject of future work and will test
our hypothesis that CAR mediated phagocytosis leads to the presentation of tumor neoantigens and thus epitope spreading.

Furthermore, we tested the durability of the adenovirally induced M1 phenotype by
challenging macrophages with the classic M2 inducing cytokines IL-4 and IL-13. CAR,
but not control, macrophages were relatively resistant to the immunosuppressive
polarization by the M2-inducing cytokines. Taken together, these results show that
Ad5f35 transduced CAR macrophages have the potential to phagocytose tumor cells,
process and present antigens, and actively co-stimulate tumor reactive T cells – leading to
a multi-modal approach to the treatment of cancer.

The tumor microenvironment is highly variable and complex, and every tumor is unique.
While we demonstrate resistance to the two canonical M2 inducing cytokines IL-4 and
IL-13, the response to other immunosuppressive factors, such as interaction with
eicosanoids, metabolic intermediates, hypoxic conditions, or other cytokines remains to
be determined. Accurately modeling the TME in vitro is an outstanding challenge in the
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field, and immunodeficient xenograft models lack central TME components. Future preclinical and clinical studies will assess the maintenance of the M1 phenotype in CAR
macrophages within the tumor of syngeneic/humanized mice and in the biopsy material
from human patients.

In conclusion, our findings support the concept that macrophages derived from human
peripheral blood monocytes can be directed to exert potent anti-tumor activity via the
introduction of a CAR, primarily through phagocytosis. We demonstrated that human
macrophages can be engineered to express a CAR with high efficiency using Ad5f35, and
that HER2-redirected human CAR macrophages reduced tumor burden and prolonged
overall survival in xenograft models. Furthermore, our data show that Ad5f35
transduction polarized macrophages toward a unique pro-inflammatory/anti-tumor M1
phenotype, led to enhanced T-cell priming, and reduced susceptibility to
immunosuppressive M2-inducing cytokines. Taken together, our results introduce CAR
macrophages as a novel adoptive cellular therapy platform for the treatment of human
cancer.
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